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ABSTRACT 
Longitudinal Study of Antimicrobial Resistance among Escherichia coli Isolated from 
Integrated Multi-site Cohorts of Humans and Swine. (December 2007) 
Walid Qasim Mohammad Alali, D.V.M., Jordan University of Science and Technology; 
M.S., Kansas State University 
Chair of Advisory Committee:   Dr. H. Morgan Scott 
Many studies have attempted to link antimicrobial use in food animal agriculture 
with an increased risk of antimicrobial-resistant (AR) bacterial levels in humans.  Our 
data arise from longitudinal aggregated fecal samples in a 3-year cohort study of 
vertically integrated populations of human workers and consumers, and swine.  Human 
and swine E. coli isolates (N = 2130 and 3485, respectively) were tested for 
antimicrobial susceptibility using the Sensititre
TM
 broth microdilution system.  The 
associations between AR prevalence for each antimicrobial agent, multi-drug resistant E. 
coli, or multivariate AR E. coli, and the risk factors (host species, production type 
(swine), vocation (human swine worker versus non-worker), and season) in the study 
were assessed using generalized estimating equations (GEE), GLM with multinomial 
distribution, or GEE in a multivariate model using a SAS
®
 macro to adjust for the 
correlated AR phenotypes.  There were significant (p < 0.05) differences in AR isolates: 
1) between host-species with swine at higher risk for ceftiofur, chloramphenicol, 
gentamicin, kanamycin, streptomycin, sulfisoxazole, and tetracycline.  The prevalence of 
ciprofloxacin, nalidixic acid, and trimethoprim/sulfamethoxazole resistance were higher 
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among human isolates, 2) swine production group was significantly associated with AR 
with purchased boars, nursery piglets, and breeding boars at a higher risk of resistance to 
streptomycin and tetracycline, and 3) human swine worker cohorts exhibited an elevated 
tetracycline prevalence, but lowered sulfisoxazole prevalence when compared to non-
workers.  High variability among seasonal samples over the 3-year period was observed.  
There were significant differences in multiple resistance isolates between host species, 
with swine at higher risk than humans of carrying multi-resistant strains; however, no 
significant differences in multiple resistance isolates within humans by vocation or 
within swine by production group.  The odds-ratios, adjusted for multivariate 
dependence of individual AR phenotypes, were increased relative to unadjusted odds-
ratios among 1) swine as compared to human for tetracycline (OR = 21.8 vs. 19.6), and 
2) increased significantly among swine-workers as compared to non-workers only for 
tetracycline (OR = 1.4 vs. 1.3).  Occupational exposure to swine-rearing facilities 
appears to be associated with an increased relative odds for the prevalence of 
tetracycline resistance compared to non-workers. 
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This dissertation follows the style of Preventive Veterinary Medicine. 
1 
CHAPTER I 
ITRODUCTIO 
1.1.  Background 
Antimicrobial agents, which include antibiotics, rank among the greatest discoveries 
in the history of human kind.  They are essential in the treatment of infectious diseases 
as well as in disease prophylaxis in human and veterinary medicine.  Antimicrobial 
resistance (AR) emergence, dissemination, propagation, and maintenance among 
bacteria have become a world wide health concern, especially in human and veterinary 
medicine (Anderson, 1999; Levy and Marshall, 2004; WHO, 2001).  The misuse and 
intensive use of therapeutic forms of antimicrobial agents in human medicine and 
companion animals, as well as the therapeutic use, prophylactic use, and subtherapeutic 
use for growth promotion in food animals have substantially increased selective 
pressures on bacteria; favoring the propagation and maintenance of AR bacteria (Levy, 
2002).  The lack of response to first line of medications (i.e., antimicrobial agents), the 
need for second or third line of treatment (more potent agents), the increased cost of 
individual treatment, the spread of nosocomial infections, and the development of multi-
drug resistant pathogenic strains are serious health problems attributed to the AR 
bacteria dilemma (Kollef and Fraser, 2001).  Nosocomial infections, which arise in 
hospital settings, have been reported in 5 – 6% of hospitalized patients (Horan et al., 
1986).  Increasing numbers of these infections are caused by AR bacteria that circulate 
in many hospital settings in different parts of the world.  The frequency of AR bacteria 
generally varies between the hospital environment and the outside community due to the 
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differences in the antimicrobial selective pressures and the availability of sensitive and 
resistant strains (Lipsitch, 2001).   
Antimicrobial resistance can develop in commensal (normal microflora) and 
pathogenic bacteria both in human and animal gastrointestinal tracts as well as in the 
environment.  It has been suggested that AR genes existed in microorganisms long 
before antimicrobial use began (Levy, 2002).  Antimicrobial resistance genes are known 
to reside on several genetic structures in bacterial cells such as the genome, plasmids, 
transposons, and integrons (Barbosa and Levy, 2000; Levy, 2002).  Mutations in the 
bacterial genetic material (i.e., DNA) that lead to AR, as well as the exchange of AR 
genes (conjugation, transformation, transduction) among bacteria (same or different 
species), have a significant role in the transmission dynamics of AR bacteria within and 
among human and animal populations.  Furthermore, cross-resistance and co-selection 
of AR genes (Courvalin and Trieu-Cuot, 2001), and persistence of these genes in human 
and animal populations, as well as in the environment, even after banning the use of 
antimicrobial agents (e.g., in Denmark (Aarestrup et al., 2001)), have added to the 
propagation and maintenance of AR bacteria in the community.   
Many authors have attempted to link antimicrobial use in food animal agriculture 
with an increased risk of AR bacterial levels in humans (Stobberingh et al., 1999; White 
et al., 2001; Winokur et al., 2001).  These authors have speculated that AR bacteria in 
animals could transfer to human populations mainly through direct contact (e.g., 
occupational exposure) and indirect contact with animals (e.g., consumption of 
contaminated food products of animal origin).  However, those studies were based on 
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historical (typically cross-sectional) data lacking a temporal component to better 
establish cause-effect relationships.  Moreover, it has been suggested that antimicrobial 
use on farms is not the only risk factor that affects resistance levels in animals 
(Kummerer, 2003; Singer et al., 2006).     
The need for empirical identification and quantification of AR genes in animal 
populations, in addition to tracking the spread of AR bacteria to human and animal 
populations, is imperative (Singer et al., 2003).  Advances in this area will facilitate the 
assessment of transmission risk and dynamics of AR bacteria among human and animal 
cohorts.  In several AR studies, assessments of human exposure to AR bacteria from 
animals, and food products of animal origin, in relation to resistance levels in human 
populations have lacked the control of several essential factors.  These include: 1) open 
study populations with limited or no control over the in- and out-migration of subjects 
(humans or animals) in the study areas, 2) human travel and trade (animals and food 
products), which serve as a source for AR bacteria that can be introduced into 
susceptible populations, and 3) lack of temporal components, as in cohort studies, which 
require follow-up of individual or groups of subjects (i.e., humans and animals) over a 
period of time (Aubry-Damon et al., 2004; Bates et al., 1994; Nijsten et al., 1994; 
Nijsten et al., 1996b; Stobberingh et al., 1999; Van den Bogaard et al., 2001; Van den 
Bogaard et al., 2002).   
Our study design and study population have effectively controlled many of the 
limitations that plagued previous AR studies.  Our agri-food study model was a multi-
site housing and vertically integrated swine and human population system in Texas.  
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There was a very limited in- and out- migration of humans to and from the system.  
Swine were moved from farrow-finish on to grower/finisher units, then were slaughtered 
and processed within the system and fed back to humans in the system.  The research 
project was a 3-year longitudinal study (January 2004 – January 2007) and samples were 
collected monthly at the group-level. 
1.2. Study objectives  
The objectives of this 3-year longitudinal study were 1) to examine the relationship 
between the prevalence of AR commensal E. coli isolated from human wastewater and 
swine fecal samples of group-level cohorts of human and swine and potential risk 
factors: host species (swine versus human), swine production type (e.g., 
breeding/gestation, farrowing, nursery, grower, finisher), human vocation (swine worker 
versus non-worker), human consumer versus non-consumer, and season, in a multi-site 
housing, vertically integrated swine and human population agri-food system, and 2) to 
compare the quantities of the ceftiofur resistant gene (blaCMY2) standardized to a bacterial 
reference gene (rpoB) in the total community DNA extracted from the human 
wastewater and swine fecal samples in relation to the risk factors in the study. 
 
  
 
5 
CHAPTER II 
LITERATURE REVIEW 
2.1.  Antimicrobial-resistant enteric bacteria in agri-food systems and risks to public 
health 
The majority of the existing AR research has focused on: 1) the relationship between 
antimicrobial use and resistance levels in human and animal populations, 2) the 
transmission of resistant bacteria from animals to humans, and 3) the clinical 
implications of resistance levels in both species.  In general, AR bacteria can be 
transmitted to humans from several different sources: 1) AR bacteria from slaughtered 
animals may contaminate the carcass meat and other animal food products, which then 
could enter the food chain, 2) humans and animals shed AR enteric bacteria into fecal 
matter such as sewage, which in turn may contaminate agriculture crops or water 
supplies, and then may enter the food chain, 3) wild animals, such as rodents and birds, 
that acquire and shed resistant bacteria, may contaminate animal feed, agriculture crops, 
and water supplies, 4) human direct contact (i.e., occupational exposure) with animals 
(pets and food animals) that are shedding AR bacteria, or 5) food handlers (rather than 
consumers) may acquire resistant organisms through exposure to contaminated animal 
food products (Phillips et al., 2004).   
Vancomycin-resistant Enterococci bacteria (VRE) were isolated from a wastewater 
treatment plant that drained from a hospital, an urban community, and from both (mixed-
influent) in Oxford, England (Bates et al., 1994).  The number of human wastewater 
samples was not specified in the study.  The authors of that study isolated VRE bacteria 
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from fecal samples collected from the following “non-human” sources: 1) pigs (n = 36) 
from a facility at the University of Oxford, 2) poultry, cattle, sheep, pigs, and horses 
from a farm 16 km outside the city (total n = 16), and 3) fresh (n = 3) and frozen (n = 2) 
chicken carcasses samples from local retail stores.  Enterococcus faecium isolates were 
tested for vancomycin susceptibility using kanamycin aesulin azide (KAA) selective 
agar supplemented with vancomycin (40 mg/L).  The VRE isolates were screened for  
the vanA gene using PCR and then ribotyped to test for genetic similarity based on the 
rRNA gene.  There were 14, 12, and 9 vancomycin-resistant Enterococcus faecium 
isolates obtained from the hospital, community, and the mixed-human drainage, 
respectively.  Fifteen of the pig fecal samples, all the fresh chicken samples, and 1 
sample each from turkey, live chicken, and pony samples also had vancomycin-resistant 
E. faecium isolates.  The authors reported that some of the clinical human isolates were 
genetically similar (i.e., had indistinguishable bands on ribotyping) to some of the non-
human strains.  The authors suggested that animals may have acted as VRE reservoirs 
due to the selection pressure applied by the use of certain antimicrobial agents (i.e., 
growth-promoters), which in turn may have increased the risk of AR bacteria 
transmission to humans via the food chain.  Their study failed to report the historical 
antimicrobial use in the “non-human” (i.e., live animals) populations.  Thus, the claim of 
association between level of VRE isolates and antimicrobial use cannot be established.  
Additionally, the ribotyping results provided no information on the VRE isolates 
dynamics of transmission; that is, though the genes were indistinguishable, the direction 
of spread (from animal to human, or vice versa) remains unknown.  
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The prevalences of AR E. coli among individual human fecal samples were 
estimated for 3 human populations in The Netherlands (Nijsten et al., 1994).  The 
populations and number of fecal samples collected were as follows: farm workers (i.e., 
pig farmers, n = 290), abattoir workers (n = 316), and with suburban residents serving as 
a control group (n = 160).  Information was also collected on recent antimicrobial use 
and hospital visits for the first 2 populations.  Fecal samples were cultivated on selective 
media supplemented with and without antibiotics.  Overall, differences were noticed 
among the three populations with pig farmers exhibiting the highest AR prevalence 
among enteric bacteria across all antimicrobial agents when compared to abattoir 
workers and suburban residents.  Suburban residents had the lowest overall AR 
prevalence.  There was no significant difference between: 1) the level of resistance 
among those abattoir workers with or without direct contact with pig fecal contents or 
pig carcasses, 2) abattoir workers with or without exposure to domestic animals, or 3) 
among the study populations that had a recent use of antibiotic or not, or that had a 
recent stay at the hospital or not.  The authors suggested that contact with livestock or 
pig carcasses increased the risk of AR bacteria transmission to humans.  By examining 
the control group we find that 1) the selection of study subjects was anonymous, and 2) 
no information on the exposure status of the suburban residents to pets and other 
livestock was provided.  The lack of information on: 1) food consumption (e.g., pork), 2) 
exposure to different animal species, and 3) movement (i.e., in- and out-migration) of 
individuals in the 3 populations, could possibly bias the observed AR prevalence 
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differences in the study.  Furthermore, since this was a cross-sectional study, a cause and 
effect relationship could not be definitively established.   
To assess the risk of AR bacterial transmission to humans through direct exposure to 
animals, Nijsten et al., (1996b) compared the prevalence of AR E. coli isolated from pig 
farmers and their reared pigs.  Individual fecal samples were collected from the farmers 
(total n = 290), and composite fecal samples were collected from either 3 breeding sows 
or finisher pigs per farm (total n = 291).  The authors did not specify the sampling 
method for farmers; that is, whether it was random or convenient.  The selection of 2 
swine production groups (mature pigs or finisher pigs) does not fully represent the risk 
of farmer exposure to other swine groups (e.g., farrowing sows and piglets, nursery 
piglets, grower pigs) that could bias the association between exposure to pigs and the 
resistance levels in farmers.  Ninety-two % (266/290) and 98% (285/291) of the fecal 
samples had E. coli growth on unsupplemented agar from farmers and pigs, respectively.  
The prevalence of both single and multiple AR E. coli isolates from pig feces was 
significantly (p ≤ 0.05) higher than those from farmers.  When E. coli resistance profiles 
were compared within the same farm, only 4% (10) of the isolates were similar.  It was 
suggested by the authors that the AR E. coli isolated from farmers and their pigs were 
different.  In other words, pigs were not considered as an important source of ‘direct’ 
transmission for AR E. coli to farmers.  There was no statistical analysis conducted to 
examine the within and between farm variability in the study since the data were 
collected at the individual-level.  Furthermore, the authors did not control for the farm-
level effect.  This study represents another open-population based research project.  
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Therefore, there was no control over the farmer population exposure to additional risk 
factors such as meat consumption, exposure to outside travel, pets, and other farm 
animals.     
Further, to investigate the potential transmission of fecal AR E. coli isolated from 
pigs and their owners (Nijsten et al., 1996a), plasmid analysis of selected isolates as 
performed by in-vitro conjugation of donor and recipient strains.  The ‘selected’ E. coli 
isolates (donors) were represented in 2 groups: 1) 10 pairs of isolates with similar 
resistance phenotypes obtained from farmers and their pigs on the same farm, and 2) 13 
randomly chosen E. coli isolate pairs with different resistant phenotypes obtained from 
fecal samples of farmers and their pigs from another farm.  The nalidixic acid-resistant 
E. coli K12 strain was used as a recipient bacterium.  This strain was susceptible to all 
other antimicrobial agents used in the study.  The frequencies of plasmid transfer were 
calculated as the proportion of transconjugants in the colony-forming unit (CFU) of the 
donor strains on a selective media treated with antibiotics.  There were 6 isolates from 
farmers, and 6 from their pigs, each subjected to conjugation with susceptible control 
isolates obtained from pigs (other than the study population) and humans (i.e., 
community residents other than the pig farmers).  The authors hypothesized that the first 
group would have more similar phenotypes among the E. coli (recipient isolates) than 
the second group.  There was a higher overall transfer rate from pig isolates than from 
farmer isolates.  There was no evidence of transfer of resistance plasmids between pig 
and farmer isolates.  The authors concluded that there was no common transfer of 
resistance plasmids between fecal E. coli isolates from farmers and their pigs.  In their 
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study, Nijsten et al. (1996a) assumed that resistance genes reside only on plasmids.  It 
has been demonstrated that resistance genes can be located on other genetic elements, 
such as transposons and integrons (Hall and Collis, 1998).  Therefore, plasmid analysis 
alone does not account for resistance genes in other cellular locations.  This could bias 
the quantification of the AR actual phenotypes that transferred from the donor to the 
recipient cells.  
The AR levels among commensal bacterial flora isolated from pig farmers (n = 113, 
exposed) and non-farmers (n = 113, control) were compared by Aubry-Damon et al. 
(2004).  The study populations were selected via an agricultural health-insurance service 
in France.  One farmer was randomly chosen per farm, and one non-farmer (control) was 
selected for each farmer and matched for sex, age, and county of residence.  Data on 
antimicrobial use and hospital visits in the past 6 months were collected for both groups.  
Nasal, pharyngeal, and fecal samples were obtained from the study participants, cultured 
for commensal bacteria and tested for antimicrobial susceptibility using a disk diffusion 
method.  Historical antimicrobial use was not significantly different (p < 0.01) between 
farmers and non-farmers.  The prevalence of Staphylococcus aureus isolates from the 
nasal and pharyngeal samples was significantly (p < 0.01) higher in pig farmers than 
non-farmers.  The prevalences of fecal E. coli isolates resistant to tetracycline, 
streptomycin, and nalidixic acid were significantly (p < 0.01) higher in farmers when 
compared to non-farmers.  The authors suggested that direct exposure of farmers to pigs 
was associated with carriage of higher levels of AR commensal bacteria.  Farmer 
exposures to AR bacteria and to antimicrobial agents were explained as follows: direct 
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contact with pigs and their feces (given that pigs were shedding AR bacteria), farmers’ 
exposure to antimicrobial agents in the work environment (for example, antibiotic 
residues and dust), and farmers could have received more antimicrobial agents due to 
medical reasons (occupational hazard) as compared to non-farmers.  This study has been 
classified as “cross-sectional” although the 2 groups were selected based on exposure, 
which is not typical for this type of study design, especially when matching was applied 
based on exposure.  Typically, in cross-sectional studies individuals are selected and 
then their exposure and outcome status at a single point of time are assessed.  The non-
exposed individuals’ selection in this study could have been improved if the authors had 
chosen subjects that lived in a similar environment as the farmers, yet were not exposed 
to the pigs or to the farmers themselves.  The consumption of food products from animal 
origin, and consequently the risk of acquiring AR bacteria through food consumption in 
the 2 groups, could have been different; however, this was not assessed in the study.  
Matching of farmers and non-farmers by age, sex, and county of residence do not truly 
control for this difference.  Furthermore, the exposure of both farmers and non-farmers 
to other farm animals and pets, travel, and food consumption were not assessed in the 
study.   
Antimicrobial resistance phenotypes and genotypes for Enterococcus faecalis and 
Enterococcus faecium isolated from humans, broiler chicken and pigs were compared by 
Aarestrup et al. (2000).  Stool samples (n = 254) were obtained from healthy humans 
with no recent history of antimicrobial use or hospital visits.  These stool samples were 
collected as a component of diagnostic samples submitted for diarrheal pathogen 
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detection.  The animal isolates (n = 2372) were obtained from the Danish Integrated 
Antimicrobial Resistance Monitoring and Research Programme (DANMAP) 
antimicrobial surveillance program in 1998.  All E. faecalis and E. faecium isolates for 
the first 9 months of the surveillance program were assessed.  One isolate per human 
sample and all isolates from broilers and pigs for both bacterial species were tested for 
antimicrobial susceptibility using Mueller-Hinton-II agar plates with 2-fold serial 
dilutions to different antimicrobial agents.  Minimum inhibitory concentration (MIC) 
was defined as the lowest concentration with no visible growth on the agar plate.  The 
presence or absence of genes conferring resistance to aminoglycosides, chloramphenicol, 
macrolides, and tetracycline among E. faecalis and E. faecium isolates from human, 
broilers, and pigs was determined using polymerase chain reaction (PCR).  One VRE 
isolate was recovered out of 38 human samples tested using selective enrichment media 
treated with 20 µg/ml vancomycin.  The prevalence of resistant E. faecalis isolates for 
chloramphenicol, kanamycin and streptomycin from humans (14%, 18%, and 20%, 
respectively) was higher than those isolated from broilers (2%, 2%, and 10%, 
respectively) and pigs (4%, 24%, and 39%, respectively).  However, prevalence of E. 
faecalis isolates resistant to bacitracin, erythromycin and tetracycline from pigs (11%, 
85%, and 68%, respectively) and broilers (60%, 44%, and 59%, respectively) was higher 
than those isolated from humans (17%, 22%, and 37%, respectively).  The prevalence of 
E. faecium isolates resistant to kanamycin from pigs (18%) was higher than humans 
(12%), and broilers (1%), but higher for vancomycin, erythromycin, 
quinupristin/dalfopristin, virginiamycin, and tetracycline in broiler (10%, 74%, 79%, 
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75%, and 32%, respectively) and pig (17%, 81%, 60%, 85%, and 63%, respectively) 
isolates than in human isolates (0%, 20%, 11%, 45%, and 12%, respectively).  Similar 
single resistance, and resistance to 2 antimicrobial agent, phenotypes were detected 
among the human, broiler and pig E. faecalis or E. faecium isolates.  All 
chloramphenicol resistant isolates from the 3 populations harbored the chloramphenicol 
resistance gene: cat-pIP501, while the tested tetracycline resistance genes were detected in 
some but not all tetracycline phenotypic resistance isolates.  Similar genotypes were 
detected among human, broiler and pig isolates.  Thus, the authors suggested that 
transmission of AR Enterococci bacteria and AR genes had taken place between 
humans, broilers, and pigs based on the similarity in phenotypes and genotypes among 
E. faecalis and E. faecium isolates.  However, the similarity of the isolate phenotypes 
and genotypes from both human, and animals do not conclusively demonstrate AR 
bacterial transmission.  In addition, similarity among phenotypes and genotypes could 
have happened simply by chance, since none of the reported unique phenotypes and 
genotype was followed over time.  Clinical human isolates from the DANMAP program 
do not represent the ‘true’ status of AR commensal bacteria among ‘healthy’ humans 
and food animals and therefore results are susceptible to bias. 
The hypothesis of whether the ingestion of meat contaminated with AR Enterococci 
can colonize the human intestine was tested in a randomized experimental trial by 
Sorensen et al. (2001).  Eighteen healthy human individuals agreed to participate and 
received no antimicrobial agents for at least one month prior the start of the study.  
These persons were randomly divided into 3 treatment groups:  Group 1: subjects 
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ingested a prepared mixture of 2 strains of glycopeptide-resistant E. faecium (10
7
 CFU) 
isolated from retail chickens, and these strains also carried the vancomycin-resistance 
gene (vanA); Group 2: subjects ingested one streptogramin-resistant E. faecium strain 
(10
7
 CFU) isolated from a pig carcass that also carried the vatD gene (another 
vancomycin resistance gene); Group 3: subjects ingested one strain of E. faecium 
susceptible to both glycopeptide and streptogramins (10
7
 CFU) isolated from retail 
chicken.  All strains were obtained from the Danish Veterinary Laboratory and the 
bacterial suspension was added to 250-ml of whole milk before being given to the 
subjects, to yield a final total dose of 10
7
 bacteria.  Those strains that were obtained from 
the laboratory were not tested for antimicrobial susceptibility before preparing the 
inoculum (e.g., culture of the strains on antibiotic-supplemented media) in order to 
reconfirm their resistance to the glycopeptide and streptogramins.  Some of these strains 
could have dropped their resistance plasmids/genes due to the subculture process (Smith 
and Bidochka, 1998).  This is a small sample size (6 subjects per treatment group) with 
which to detect a statistically significant difference when it exists (low power).  Stool 
samples from the participants were collected 2 days before ingestion, daily for one week, 
and then again at 14 and 35 days post-ingestion.  Samples were cultured on bile esculin 
azide (BE) agar plated treated with vancomycin, virginiamycin, erythromycin, or 
azteronam, based on the day of sampling.  The authors did not plate all the stool samples 
on the same antibiotic supplemented agar, which makes it difficult to compare resistance 
levels to individual antimicrobial agents among the 3 groups at once, and over time.  The 
obtained isolates were typed using pulsed field gel electrophoresis (PFGE) to determine 
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their genetic similarity.  There were no glycopeptide-resistant or streptogramin-resistant 
E. faecium strains isolated from the subjects before the ingestion.  The authors could 
have sampled the subjects multiple times before ingestion (in order to determine possible 
intermittent shedding) to affirm that subjects were actually free of resistant E. faecium 
strains.  Group 1 subjects shed glycopeptide-resistant E. faecium during the 1
st
 week, 
with peak concentrations on days 2 and 3 (2x10
4
 to 1x10
8
 CFU/g) while none were 
detectable from subjects at days 14 and 35.  Group 2 subjects had streptogramin-resistant 
E. faecium detected during the 1
st
 week (peaks on days 2, 3, 4 and 5 with 10
4
 CFU/g), 
from one subject at day 14, and none at day 35.  One subject in group 2 shed 
glycopeptide-resistant E. faecium on days 5 and 6 (8x10
3
 CFU/g), but this strain had a 
different PFGE pattern than the ingested strains.  Group 3 subjects had no glycopeptide-
resistant or streptogramin-resistant E. faecium isolated.  PFGE showed that the E. 
faecium strains from groups 1 and 2 were similar  to the strains that had been ingested 
(other than the single isolate from one subject in group 2, as noted above).  The authors 
suggested that AR Enterococci isolates from retail chicken and pork can colonize, 
survive, and pass through the human intestines for up to 14 days after ingestion.  Based 
on these findings, they recommended that antimicrobial agents be discontinued as 
growth promoters in animal feed.    
In another study,in order to provide evidence of VRE bacteria transmission from 
animals to humans, fecal samples were collected from: turkeys (n = 81) and their farmers 
(n = 81), turkey slaughter-house workers (n = 100), and suburban residents (n = 200) in 
the Netherlands (Stobberingh et al., 1999).  The last group was randomly selected from a 
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telephone directory of people living in the same province as the farms.  The study 
participants were asked to complete a questionnaire concerning recent hospital visits, 
antimicrobial agents used by themselves and in their animals, and whether they owned 
pet animals or not.  Samples were cultured on Kenner fecal (KF) Streptococcus agar 
(with and without vancomycin), then antimicrobial susceptibility to several agents was 
determined using the broth microdilution method in Iso-Sensitest Broth (CM473; Oxoid, 
UK).  Vancomycin-resistant Enterococci strains were screened for the presence of vanA, 
vanB, and vanC genes using PCR.  VRE strains were typed using PFGE to assess their 
genetic similarity.  In addition, vanA-containing transposons in these isolates were 
characterized using restricted fragment length polymorphism (RFLP) analysis.  DNA 
sequencing was performed on the PCR products.  There were no differences between the 
isolates from farms that used avoparcin and those that did not.  Avoparcin is a 
glycopeptide that has demonstrated cross-resistance with vancomycin in The 
Netherlands.  There was a total of 283 Enterococci isolates in general, and 59 VRE 
isolates from all the samples tested.  The VRE isolates were mainly E. faecium strains, 
followed by E. faecalis.  The percentages of VRE isolates that harbored the vanA gene 
from turkeys, turkey farmers, turkey slaughter-house workers, and suburban residents 
were 35.6, 22.0, 16.9, and 23.7, respectively.  The PFGE analysis demonstrated 
heterogeneity among the VRE isolates, although a vanA transposon was identical in 3 
turkeys and those turkey farmers’ VRE isolates arising from the same farm.  Based on 
PFGE results demonstrating that turkeys and turkey farmers have different enterococcal 
strains, the authors have suggested that it is less likely for turkey isolates to colonize the 
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human gut for extended periods of time.  However, they reported that VRE isolates were 
capable of being transmitted from turkeys to the turkey farmers because of the vanA 
transposon detection in strains isolated from both species from the same farm.  The 
authors failed to state that animal isolates are not the only source of AR bacteria.  Other 
sources (e.g., wild animals, pets, food, and other humans) that shed, or are contaminated 
with isolates harboring the vanA gene and/or the transposon can pass the 
gene/Enterococci strains to farm animals and humans. 
Van den Bogaard et al. (2001) reported the prevalence and degree of resistance 
among fecal E. coli isolated from: 1) turkeys (n = 47), turkey farmers (n = 47), and 
turkey slaughter-house workers (n = 47), 2) broilers (n = 50), broiler farmers (n = 51), 
and broiler slaughter-house workers (n = 46), and 3) laying-hens (n = 25) and laying-hen 
farmers (n = 25).  One-time individual fecal samples from human subjects and 
composite fecal samples from poultry were collected.  Questionnaires were used to 
collect information from human subjects on antimicrobial use and hospital visits in the 
previous 3 months, as well as on contact with other animals.  Escherichia coli bacteria 
were cultured on Levine agar (Becton Dickenson BV, Etten-Leur, The Netherlands) and 
tested for antimicrobial susceptibility by randomly choosing one colony and testing it 
using Iso-Sensitest broth microdilution.  Ciprofloxacin-resistant E. coli isolates were 
genotyped using PFGE to assess their genetic similarity.  None of the study subjects had 
received any antimicrobial agents, except for 4 broiler farmers and 4 broiler slaughter-
house workers.  Hospital visits were reported only for 2 broiler slaughter-house workers 
and one laying-hen farmer.  The highest overall AR prevalence among poultry was for 
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turkey isolates, then broilers, and lowest for laying-hen isolates.  This finding was 
explained by the relatively high levels of antimicrobial use in turkeys and broilers 
compared to relatively little use in laying-hens.  Among human populations, turkey 
farmer isolates had the highest overall AR prevalence and the lowest prevalence was for 
laying-hen farmers.  The resistance levels were similar among turkey and broiler 
slaughter-house workers.  Similar AR phenotypes were observed among turkeys, turkey 
farmers, and turkey slaughter-house workers.  The most common multi-resistant AR 
pattern was oxytetracycline- amoxicillin- streptomycin- sulphamethoxazole-
trimethoprim.  The authors did not specify whether the poultry sent to the slaughter 
house were coming from the participating farms or from any other farms (i.e., slaughter 
house workers could have been exposed to a variety of sources of poultry).  The PFGE 
analysis showed heterogeneous patterns of ciprofloxacin-resistant E. coli isolates.  There 
were 5 similar patterns found in E. coli isolates from turkey and turkey farmers from the 
same farm, and in one broiler and broiler farmers from different farms.  The authors 
hypothesized that more similar patterns would have been detected if more than 1 
ciprofloxacin-resistant E. coli colony per sample had been selected.  They concluded that 
AR bacterial transmission occurred from animals to humans based on the isolates’ clonal 
patterns.  However, the authors did not address the source of AR bacteria nor did they 
determine their temporal relations.  The authors did not control for the risk of AR 
bacteria due to consumption of food products of animal origin. 
The prevalence of resistance of fecal Enterococci isolated from: 1) broilers (n = 51), 
broiler farmers (n = 51) and broiler slaughter-house workers (n = 46), 2) laying-hens (n 
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= 26) and laying-hen farmers (n = 26) in The Netherlands was further examined by Van 
den Bogaard et al. (2002).  Individual fecal samples from humans and composite fecal 
samples from poultry were collected at a single point in time.  Questionnaires were used 
to collect information regarding human antimicrobial use and hospital visits in the 
previous 3 months, as well as contact with other animals.  This study was conducted 
approximately 6 months after the suspension of the use of avoparcin in Europe (an 
antimicrobial agent similar to vancomycin).  Enterococci strains were isolated on KF-
Streptococcus agar with, or without, vancomycin and were tested for antimicrobial 
susceptibility by randomly choosing one colony and then testing it using Iso-Sensitest 
broth microdilution.  VRE that were recovered from the same farm (poultry and farmer) 
were later subjected to PFGE typing, vanA transposon analysis using restriction 
fragment length polymorphism (RFLP), DNA sequencing of the transposon gene PCR 
product, and by hybridization to test for the presence of vanA, vanB, and vanC genes.  
The Enterococci recovery percentages ranged from 89 – 96% per sample.  Eighty-four 
VRE isolates were recovered with, and without, enrichment.  Seventy-three VRE 
isolates were hybridized and showed the presence of vanA gene only.  The majority of 
isolates that harbored the vanA gene were E. faecium (n = 41), and to a lesser extent E. 
faecalis (n = 5), E. hirae (n = 16), and E. durans (n = 9).  The overall prevalence of AR 
was highest among Enterococci isolated from broiler fecal samples.  The prevalence of 
resistance to vancomycin was significantly higher among broiler farmers’ isolates than 
either laying-hen farmers or broiler slaughter-house workers.  The authors did not collect 
information on food exposure (e.g., meat consumption) of the sampled populations.  
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Only 2 farms out of the 10 had Enterococci isolates in which VRE bacteria from broilers 
and farmers at the same farm were identical based on the PFGE analysis.  Three out of 
eight vanA transposon types, detected in the VRE isolates from broilers and farmers, 
were identical.  On the basis of this study, the authors suggested that farmer exposure to 
poultry was a risk factor for AR bacteria dissemination and human gut colonization, 
specifically Enterococci strains.  The evidence of AR bacteria transmission from animals 
to humans claimed by the authors is clearly circumstantial (cross-sectional) and lacks a 
temporal component.  Additionally, their study lacks the temporal tracking of resistance 
markers among and within both species. 
2.2.  Assessing antimicrobial resistance using phenotypes 
Measuring the phenotypic resistance of commensal and pathogenic bacteria is the 
most common method of assessing AR in human and animal populations.  Antimicrobial 
resistance phenotypes are the in vitro characteristics of bacterial isolate resistance 
against the action of one or more antimicrobial agents.  These characteristics may be 
measured using several different methods, such as broth microdilution and disk diffusion 
(Wheat, 2001).  The MIC values or the zone of inhibition are usually further categorized 
into resistant, intermediate, or susceptible based on pre-determined breakpoints.  
Resistance profiles for a bacterial isolate can range from pansusceptible through 
resistance to multiple antimicrobial agents.  Several cross-sectional studies have focused 
on estimating the prevalence of single and multi-drug resistance of specific commensal 
or pathogenic bacteria in human and/or animal populations.  Thereafter, several of those 
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studies also tried to assess the association between the AR phenotypic estimates and 
other risk factors.   
As part of a surveillance program in Spain to monitor AR bacteria in livestock, 220 
samples (one sample/pig) were collected from the colon of pigs (Teshager et al., 2000).  
Collection was performed at 4 different slaughter houses over a period of 3 months.  
Escherichia coli bacteria were isolated on Drigalski agar (each agar plate represented 
one sample) and 3-4 colonies were picked from each plate and then mixed before they 
were tested for antimicrobial susceptibility using a broth microdilution method.  The 
MIC values were interpreted as breakpoints according to the National Committee for 
Clinical Laboratory Standards (NCCLS, 1999) guidelines.  The mixing approach of 3-4 
colonies from an agar plate for antimicrobial susceptibility testing can be problematic if 
the number of different resistance phenotypes per sample is greater than 1.  Hence, the 
phenotypic variability was not assessed in that study.  Based on this antimicrobial 
susceptibility testing method, samples would be more likely to be positive (i.e., resistant: 
if at least 1 colony out of 4 was resistant, the sample would be classified positive) than to 
be negative (i.e., susceptible: all 4 colonies would need to be susceptible, to be classified 
as susceptible) introducing a differential misclassification bias.  Two hundred and five E. 
coli strains were recovered (93% recovery rate).  Groups of isolates were highly resistant 
to tetracycline (95.6%), sulfamethazine (87.8%), trimethoprim (83.4%), demonstrated 
low resistance to cephalothin (16.1%), neomycin (10.7%), gentamicin (4.4%), 
ciprofloxacin (8.3%), and cefoxitin (1.5%), and exhibited total susceptibility to 
ceftazidime and cefotaxime.  This study failed to report the sampling method of the pigs 
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(e.g., random, systematic, or convenient) at the slaughter houses, and the relationship 
between sources of the pigs (i.e., farms), their antimicrobial use, and their levels of 
resistance.   
In an earlier study, Dunlop et al. (1998a) estimated the levels and patterns of AR E. 
coli isolated from finisher pigs (i.e., those within one month of slaughter).  Twenty 
composite fecal samples were collected from floors to represent different swine pens at 
each of 34 farrow-to-finish farms in Ontario, Canada.  Farm samples (n = 68) were 
collected on 2 occasions over a 4-month period of the study.  A total of 8119 E. coli 
were isolated on MacConkey agar and tested for antimicrobial susceptibility using the 
hydrophobic grid membrane filter (HGMF) method.  Briefly, an E. coli suspension was 
passed through a grid membrane filter, the filter was placed on a selective media treated 
with a specific antimicrobial agent, and then colonies were counted using the HGMF 
MI-100 Interpreter
®
 electronic counter.  If the percentage of resistant colonies on the 
filter exceeded 50% of the total colonies that grew on the filter, then the tested E. coli 
isolate was classified as resistant.  The authors did not perform a confirmatory test as to 
whether isolates obtained from MacConkey agar were E. coli or not.  The overall 
prevalences of E. coli single-resistant to ampicillin, gentamicin, sulfisoxazole, and 
tetracycline in pig samples were 29%, 0.6%, 38%, and 71% respectively.  Within-farm 
variation in the percentages of resistance was higher for all the antimicrobial agents 
tested as compared to between-farm variation.  This was explained by the differences in 
antimicrobial usage at the individual level.  However, it might have been expected that 
the variation in antimicrobial use is larger between farms compared to within farms.  The 
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authors compared their prevalence results to other studies that used disk and broth 
microdilution susceptibility methods.  Those methods are based on zones of inhibition or 
turbidity (i.e., growth), and not colony counts.  In addition, in disk and broth 
microdilution methods, isolates are commonly classified as resistant or susceptible, 
based on NCCLS (1999) standards.  The frequencies of resistance among E. coli isolates 
that were differentiated based on their resistance to other antimicrobial agents was 
assessed using an unadjusted relative risk (RR).  A strong association or ‘resistance 
traits’ linkage’ between gentamicin and sulfisoxazole (RR = 34) resistance levels was 
not further explained in the Dunlop et al. (1998a) study.  This high correlation may be 
possible if, for example; co-selection between gentamicin and sulfisoxazole existed in 
the isolates.   
The prevalence and antimicrobial susceptibility of Salmonella spp. isolates from 
beef cattle feedlots in the US were determined by Dargatz et al. (2003).  Between 1999 
and 2000, 10,417 fecal samples were collected from cattle in 422 pens in 73 feedlots in 
12 states.  Those samples were selectively cultured for Salmonella and at least 3 
colonies/ positive sample were picked and further characterized using serotyping.  These 
isolates were then tested for antimicrobial susceptibility using a custom panel of 17 
antimicrobial drugs; thereafter, MIC values were determined and interpreted as 
susceptible, intermediate, or resistant according to NCCLS (1999) breakpoints.  Of the 
713 Salmonella isolates from 654 fecal samples, 35.9% were resistant to tetracycline, 
11.1% to streptomycin, 10.4% to ampicillin, 10.4% to chloramphenicol.  Less than 10% 
of the isolates were resistant to cefoxitin, ceftiofur, ceftriaxone, cephalothin, kanamycin, 
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nalidixic acid, sulphamethoxazole, and trimethoprim/sulphamethoxazole.  None of the 
isolates were resistant to ciprofloxacin or gentamicin.  The authors reported that resistant 
isolates were clustered by pen and by feedlot.  The clustering was based on the similarity 
of the antibiograms (i.e., phenotypes) of Salmonella serotypes isolated from the same 
feedlots or pens.  However, clustering of isolates based on the similarity of phenotypes 
without a performing a formal statistical test to assess clustering in the data, and 
claiming the isolates are clonal without any genotypic analysis, is a suboptimal 
analytical approach.  In addition, there was no attempt to model or adjust for the 
hierarchical multi-level nesting and dependency in the data (i.e., cattle/pen/feedlot/state). 
In a repeated (time-series) cross-sectional study, AR patterns of E. coli were 
compared from farm animals and environmental samples collected every 3 months over 
a 12-month period (Sayah et al., 2005).  Thirty-one farms were sampled in Michigan and 
the antimicrobial use history for these farms was determined by questionnaires 
administered during the farm visits.  Fecal samples were collected per rectum from 
livestock (dairy and beef cattle, swine, horses, sheep and goats) and poultry (cloacal 
swabs), while fecal droppings from deer and wild geese, environmental samples (water 
runoff from the farms, lagoons and manure piles), and sewage samples (human fecal 
matter from septic tanks) rounded out the collection.  A total of 2,522 samples was 
collected from the 31 farms and E. coli were isolated using enrichment (Tryptic Soy 
Broth (TSB)) and culture methods (MacConkey agar) and then confirmed using 
biochemical tests (indole, methyl red, Voges-Proskauer, and Simmons citrate).  
Confirmed E. coli isolates (n = 1,286) were tested for antimicrobial susceptibility using a 
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disk diffusion method.  The diameter of zone of inhibition (measured as a continuous 
outcome) was used as is, or else was classified into resistant or susceptible according to 
NCCLS (1999) breakpoints.  Overall, the most frequent antimicrobial agent used on 
farms was penicillin (86%), followed by chlortetracycline (30%), sulfamethazine (16%), 
and oxytetracycline (14%).  The highest AR in all samples was for tetracycline (27.3%), 
followed by cephalothin (22.7%), sulfisoxazole (13.3%) and streptomycin (13.1%).  
Interestingly, E. coli isolates resistant to cephalothin were present in all samples, while 
E. coli isolates resistant to tetracycline were present in all samples except in river water.  
The highest multi-drug resistant (i.e., up to 10 – 12 different antimicrobial agents) E. coli 
isolates were found in swine samples (fecal and farm environment) and the lowest were 
found in deer and wild geese (i.e., pansusceptible and single-resistant).  In addition, 
swine exhibited the highest likelihood of shedding E. coli isolates resistant to 
tetracycline, sulfisoxazole, streptomycin, and ampicillin when compared to all other 
animals in this study.  Resistance patterns were similar between E. coli isolated from 
animal fecal samples and the farm environment.  Similar, but not identical, phenotypes 
were observed in swine and poultry isolates for tetracycline and streptomycin (high 
resistance levels) and sulfisoxazole, and cephalothin (low resistance levels).  Fifty-three 
percent of E. coli isolates were pansusceptible, 34% were resistant to 1 or 2 
antimicrobial agents, and 13% were resistant to 3 or more.  Based on the similarity in 
resistance patterns among farm animals and the environment, the authors concluded that 
livestock served as an environmental reservoir for AR bacteria.  However, in their study, 
common resistance phenotypes were examined by farm (isolates from farms with diverse 
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animal species) and by environment.  The authors could have combined both farm and 
environmental AR phenotypic data and examined the data set for common resistance 
phenotypes to better assess common sources of resistance.  They suggested that 
resistance phenotypes could be utilized to determine the source of AR bacteria, and that 
this is a preferable method to molecular approaches which are more costly and require 
more experience to perform.  It might be possible to determine the source if we track 
very unique phenotypes over time; however, culture methods have several disadvantages 
such as: missing unculturable bacterial cells, measuring gene expression versus 
presence, and selection bias associated with testing a colony or even 5 out of a sample 
that contains literally millions of bacterial types, and the length of time some bacterial 
isolates take to grow.  Molecular methods are a preferred method in many laboratories 
because of the rapid, reliable assessment of AR genes, and ability to track specific genes 
over time.  In this repeated cross-sectional study, the sampled study subjects (animals 
and environment in this study) at a single time-point were not described in the text.  
When repeated inclusion occurs, time factors can be accounted for in the analysis 
(Dohoo et al., 2003).  The seasonal (i.e., samples were collected every 3 months) effects 
were not assessed in the study by Sayah et al. (2005). 
2.3. Assessing antimicrobial resistance using genotypes 
Antimicrobial resistance genotype is defined by qualitatively or quantitatively 
measuring genetic marker(s) that code(s) for antimicrobial resistance on a bacterial 
plasmid, genome, transposon, and/or integron.  Those genotypes are characterized using 
an array of molecular methods.  The most common molecular techniques used in AR 
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research are gel-based PCR, real-time PCR, PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP), PFGE, DNA sequencing, and hybridization-based methods 
including microarrays (Woodford and Sundsfjord, 2005).  Genetic methods are known to 
have advantages over the conventional phenotypic methods for assessing antimicrobial 
resistance; however, disadvantages for these methods also exist (Cockerill, 1999).  Some 
of the advantages are: 1) genetic methods detect or quantify resistant gene(s) and not 
simply the expression of the gene (i.e., phenotypes) in vitro, 2) genetic methods can be 
applied directly to the sample (e.g., total community DNA) without the need to isolate 
the target organism, and 3) some genotypic analyses can be performed in a shorter time 
compared to than phenotypic analyses, especially when growing the organism takes a 
long time or else it cannot be cultured.  Some of the disadvantages of molecular methods 
are: 1) the sensitivity of the molecular assays can be an issue, especially when the target 
gene is below the detection limit, 2) false positives (especially with cross-amplification 
of other gene(s), contamination of the template, or primer-dimer formation), and 3) 
detecting or quantifying resistance given that multiple genes can code for resistance to 
one antimicrobial agent, such as for tetracycline (Cockerill, 1999).   
As one example, transposon (Tn) 1546, that is present in most of vancomycin 
resistant E. faecium (VREF) isolates, was characterized by the vanX gene using PCR to 
determine its base pair variation (Jensen, 1998).  A total of 271 VREF isolates from 
human, pigs and poultry were analyzed for G and T type fragments of the vanX gene.  
All poultry isolates were G type and almost all pig isolates were T type.  However, 
human isolates had both types.  The authors suggested that G type E. faecium isolates 
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from humans arose from poultry and T type arose from pigs.  Therefore, they concluded 
that horizontal transfer of VREF was from animals to humans, and was not likely to be 
animal-to-animal (i.e., poultry-to-pigs).  However, poultry and pigs could simply be 
carriers of host-specific strains and not the only reservoir or source of VREF containing 
vanX gene isolates.  Other sources (e.g., other animal species) can possibly carry this 
resistant organism and pass it to humans directly (e.g., through contact) or indirectly 
(e.g., through contaminated food and water).  Therefore, the similarity in the gene types 
in animal and human isolates does not provide clear evidence of transmission of VREF 
vanX gene and evidence that poultry and pigs were the reservoir of the isolates.  
The frequency of multiple tetracycline resistance genes in E. coli isolated from 
different animal and human populations was determined by Bryan et al. (2004).  Fecal 
samples were obtained from humans, cats, cows, deer, turkeys, ducks, sheep, geese, 
dogs, pigs, horses, chicken, and goats.  The samples were collected from a state fair, 
microbiology students at the University of Minnesota, a wildlife management area, and 
several poultry farms across the state of Minnesota.  A total of 1263 E. coli isolates were 
obtained from 87 fecal samples.  Isolates were grown on media supplemented with 
tetracycline at concentrations ranging from 5 – 233 µg/ml.  The highest resistance (≥ 233 
µg/ml) to tetracycline was found in E. coli strains isolated from pigs (61%), chickens 
(29%), and turkeys (29%).  Isolates with MIC ≥ 93 µg/ml (classified as highly resistant, 
n = 325) were tested for 14 different tetracycline resistant genes using a multiplex PCR.  
Ninety-seven of the isolates tested had at least 1 of the 14 resistant genes and the most 
common gene detected was tetB (63%) followed by tetA (35%).  More than half of the 
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tested pig and human E. coli isolates contained tetB gene.  The external validity for this 
study is questionable.  The subjects’ sampling is not representative (i.e., selection bias) 
of the general population (both humans and animals).  For example, the state fair 
animals do not represent the target population of farm animals.  Furthermore, the state 
fair animals are exposed to different sources of resistant bacteria, such as humans that 
tend them and the different environmental conditions they are exposed to.  Also, the 
antimicrobial use in these animals could be very different from farm animals.  The 
authors did not compare the genes’ frequencies with colonies cultivated on agar that 
were not supplemented with antibiotic.  On the other hand, the authors used multiplex 
PCR to test for several genes in the isolates, which reduces selection bias.  However, one 
of the major drawbacks of multiplex PCR is the complicated optimization and designing 
of multiple primers where the possibility of formation and identification of primer-
dimers and non-specific products can become a problem (Rachlin et al., 2005).   
The dissemination of tetracycline genes among Enterococci strains isolated, and 
total community DNA extracted, from 2 swine farm lagoons and downstream 
groundwater was examined by Chee-Sanford et al. (2001).  The 2 swine farms were 
grower-finishers and farrow-nursery operations, respectively.  Groundwater samples 
were collected from 20 wells downstream of the lagoons or the swine operations.  Also, 
lagoon samples were collected from both swine farm sites.  Tetracycline-resistant 
Enterococci strains were isolated from groundwater and lagoon samples on agar treated 
with 20 µg/ml tetracycline.  Several tetracycline resistant genes (O, Q, W, M, B(p), S, 
otrA, and T) were amplified from the resistant isolates (genomic DNA) and from total 
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community DNA samples using PCR.  Denaturing gradient gel electrophoresis (DGGE) 
was performed on the amplified PCR products to determine their genetic fingerprints.  
Enteroccoci isolates were recovered in high numbers (4 x 10
3
 – 3 x 10
4
 CFU/ml) from 
lagoons, and in low numbers (1.3 x 10
2
) from groundwater.  All of the tetracycline 
resistance genes were detected in the lagoon samples, but few in the groundwater.  
Identical tet(M) genes, based on the DGGE analysis, were found in lagoon and 
groundwater samples.  The authors suggested that tetracycline resistance genes were 
mobile within the environment and could be disseminated to bacteria in human drinking 
water; consequently increasing the levels of AR in human populations.  The authors did 
not identify the number of samples per lagoon, and thus we assume their interpretations 
are based on the very few results per sampling site.  A larger sample size is needed to 
capture the variability within and between samples as it relates to the tetracycline 
resistance gene diversity.  Resistant isolates carrying the gene tet(M) could have been 
present in the soil due to contamination from 1) wild animals (e.g., droppings) and hence 
reached the groundwater wells, or 2) contamination from sewage treatment plants that 
reached the wells (human source).  Based on the study findings, different tetracycline 
resistance genes appear to exist in lagoons, and to a lesser extent in groundwater, but no 
concrete evidence was provided to support the hypothesis of tetracycline-resistant 
Enterococci disseminating from lagoons to groundwater. 
Donaldson et al. (2006) isolated commensal E. coli from the feces of healthy dairy 
heifer calves and tested them for: 1) antimicrobial susceptibility to an array of 
antimicrobial agents including ceftiofur, 2) the presence of the blaCMY2 resistance gene, 
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and 3) genetic similarity using PFGE analysis.  Fecal samples (n = 20) were collected 
from healthy calves (age 1 – 9 weeks) every 4 weeks for a 5-month period on one 
Holstein dairy farm in Pennsylvania.  Newborn calves delivered between April and 
August 2003 were included in the study.  Calves on this farm often received ceftiofur 
sodium (Naxcel
®
) for scours and respiratory infection treatment.  Only those calves born 
in April 2003 were fed medicated milk replacer (supplenented with tetracycline and 
neomycin); thereafter, only non-medicated milk replacer was fed.  Fecal samples were 
cultivated on MacConkey agar with and without ceftiofur supplementation (8 µg/ml) and 
E. coli were isolated.  Susceptibility testing also was performed using a disk diffusion 
method and values interpreted using NCCLS guidelines.  Eighty-eight % of the sampled 
calves (n = 96) harbored ceftiofur-resistant E. coli isolates and the mean of the ceftiofur 
resistant E. coli CFU counts was highest in June.  Ceftiofur-resistant E. coli (n = 122) 
were genotyped using a PFGE method to assess DNA similarity of the isolates.  Also, 
these 122 isolates were screened for the blaCMY2 resistant gene using PCR.  There was no 
significant difference in the frequency of isolating ceftiofur resistant E. coli over time 
(i.e., months).  The 122 ceftiofur resistant E. coli isolates showed 27 distinct patterns 
based on the PFGE analysis.  However, 63.1% of the isolates belonged to one group 
based on cluster analysis.  A total of 117 isolates (96%) contained the blaCMY2 resistance 
gene based on PCR.  All of the 122 E. coli isolates were reported as multi-drug resistant 
to 3 or more antimicrobial agents.  In addition, it was reported in their study that calves 
as young as 1-day old were found to be shedding multi-drug resistant E. coli isolates.  
The authors concluded that young healthy calves acquired resistant E. coli shortly after 
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birth, likely from such disparate sources such as: the maternity pen, calf-to-calf contact, 
exposure to the farm workers and, contaminated drinking water.  In addition, commensal 
AR E. coli isolates from healthy calves apparently can disseminate into the dairy farm 
environment, as suggested by the authors.  It would be better if they had identified and 
followed cohorts of newborn calves (grouped around the same age) to start with, from 
different farms, and reported the E. coli resistance levels (ceftiofur resistance and 
blaCMY2) changes over time; both within as well as among calf cohorts.  Furthermore, the 
authors could have sampled the calves’ maternity pen (e.g., cow feces, pen environment, 
and workers) before and after delivery to identify potential sources of AR E. coli that 
might help to colonize the calves’ intestines.  The authors did not test the effect of actual 
treatment records of injectable ceftiofur on the level of ceftiofur resistant E. coli and the 
presence of the blaCMY2 gene. 
Gentamicin-resistant E. coli isolates (n = 78) were obtained from laboratory 
submitted cases of bovine (n = 51) and porcine (n = 27) diarrhea in Denmark and 
screened for the presence of gentamicin resistance genes and class 1 integrons using 
PCR (Sandvang and Aarestrup, 2000).  Assessment of the genetic similarity of the 
isolates was performed by PFGE analysis.  The 78 isolates were selected from a strain 
collection at the Danish Veterinary Laboratory.  Antimicrobial susceptibility testing of 
E. coli isolates to 15 antimicrobial agents, including gentamicin (40 µg (assumed to be 
per ml)), was performed by a tablet diffusion test using Neo-Sensitabs
®
 on Mueller-
Hinton II agar.  All of the gentamicin-resistant E. coli isolates were susceptible to 
amikacin, 7.6% were resistant to apramycin, 33% to neomycin, 26% to netilmicin, 90% 
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to kanamycin, and 100% to tobramycin.  None of the gentamicin-resistant isolates 
harbored the acc(6)-Ib gene, 76% of the gentamicin-resistant isolates harbored the 
ant(2”)-Ia gene (98% of cattle gentamicin-resistant isolates and 37% from swine 
gentamicin-resistant isolates), 14% of these isolates harbored the aac(3)-IIa (mainly 
from swine gentamicin-resistant isolates), and 8% of these isolates harbored the acc(3)-
IV gene (only in swine gentamicin-resistant isolates).  The PFGE analysis showed 45 
distinct patterns overall; 24 of the 51 bovine isolates had an identical pattern, and 2 of 
the 25 porcine had identical PFGE pattern.  Twenty percent (n = 16) of the 78 isolates 
were positive for class 1 integron presence.  The resulting PCR products were sequenced 
to determine the gene cassettes.  The ant(2”)-Ia gene cassette was found in low 
frequency (12% ,or 2 of the 16).  It is important to note that gentamicin has been never 
approved for use in animal agriculture in Denmark, and that other related antimicrobial 
agents (e.g., tobramycin and kanamycin) are used in very small quantities in human 
medicine.  Therefore, the authors have speculated that gentamicin resistant E. coli 
isolates may have entered the Danish farms with either imported pigs or else are due to 
co-selection with other antimicrobial agents.  In addition, the authors concluded that 
integrons did not seem to be a frequent gentamicin resistance gene carrier.  Clinical 
isolates obtained from the Danish Veterinary Laboratory are not representative of the 
‘true’ status of AR commensal bacteria in ‘healthy’ livestock in Denmark.  Therefore, 
selection bias may be an issue when making inferences about gentamicin resistance 
levels in the general healthy livestock population. 
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Three tetracycline resistance genes tet(O), tet(W), and tet(Q) were quantified in total 
community DNA extracted from feedlot lagoons using real-time PCR by Smith et al. 
(2004).  Eighteen lagoon samples were collected over a 2-month period from 7 lagoons 
in the midwestern United States.  Total community DNA was extracted from a 2-ml 
aliquot of each of the 500-ml samples using the QIAGEN DNA Stool Mini-Kit
®
.  The 
leftover lagoon sample was used to quantify: 1) tetracycline in the lagoon sample using 
an ELISA technique, 2) total suspended solids, 3) volatile suspended solids (VSS), and 
finally 4) 1-ml of the sample was directly plated on several tetracycline treated (0 – 16 
µg/ml concentration) agar plates.  Quantitative real-time PCR (qPCR) was performed by 
building standard curves from plasmids that carried the genes of interest, using a 
TaqMan assay, and reporting gene copy numbers.  Gene copy numbers were normalized 
(i.e., standardized) for the lagoon sample-to-sample variation using the VSS amounts 
(mg) in those samples.  Samples were categorized into above or below the median 
tetracycline level (1.95 µg/liter).  Without normalization, the total resistance genes, as 
well as the individual tet(O) and tet(W) genes, were significantly higher for the above-
median tetracycline samples than the below-median ones.  However, the authors did not 
present gene copy number comparisons between above and below the median 
tetracycline levels when normalized to VSS.  Instead, the authors showed that the linear 
relationship between resistance gene numbers and the tetracycline levels in the lagoon 
sample was weaker when normalized to VSS (r
2
 = 0.15) than without normalization (r
2
 = 
0.5).  They mentioned that the goal of normalizing the data was to account for the 
difference in cattle numbers and distance from the lagoons at each feedlot.  Therefore, 
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the weak relationship stated above was due to the small proportion of tetracycline 
resistant bacteria in the organic matter present in the lagoon samples.  However, the goal 
of normalization (i.e., standardization) of samples, whether using the VSS method, total 
community DNA concentration, 16S rDNA or rpoB (an RNA polymerase beta-subunit) 
copy numbers, is to account for the differences in the background bacterial populations 
that contain the resistant bacteria and their resistance gene(s).  The problem with the 
VSS method is that different lagoon samples may have different bacterial population 
sizes, but yet the same organic matter content, and thus the VSS quantity would be the 
same.  The linear relationship between the total copy numbers of the resistance genes 
(log-transformed) for each lagoon, and the log of the percentage of colonies that grew on 
plates treated with 2 µg/ml tetracycline compared to 0 µg/ml, was significantly 
correlated (r
2
 = 0.22, p = 0.022).  The authors concluded that the qPCR method can 
replace the conventional phenotypic method of measuring resistance, with the advantage 
of quantifying resistance genes in all organisms rather than simply the cultivatable ones.  
In contrast, while the conventional phenotypic method can measure bacterial 
susceptibility to many antimicrobial agents at one time, it could take much more time 
and labor to test all known resistance genes for all antimicrobial agents using real-time 
PCR (i.e., qPCR).  Therefore, while qPCR techniques have several useful applications 
(e.g., monitoring specific resistance gene levels in the environment) in assessing AR 
levels, they will never entirely replace the need for the phenotypic analysis, at least in 
the near future (Woodford and Sundsfjord, 2005).   
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Fecal commensal E. coli isolates (n = 181) obtained from healthy adults were 
characterized for the presence of integrons and their association with the isolate 
phenotypes by Shurnik et al. (2005).  The adult participants did not receive any 
antibiotics for 1 month prior to sample collection.  The study subjects represented 3 
different groups: Wayampi Amerindians living in French Guyana, pig farmers, and bank 
or insurance workers; the latter 2 groups were from western France.  There were 25 
participants per group and 4-5 isolates obtained from each subject.  Total genomic DNA 
was extracted from the pure E. coli isolates (1 isolate per distinct phenotype) and then 
tested for intI1, intI2, and intI3 genes by real-time PCR using the SYBR
®
 Green 
(Stratagene, Inc., La Jolla, CA, USA) assay.  The PCR-products were sequenced to 
differentiate the gene cassettes on each of the integrons.  There was a total of 27 (15%) 
integron positive isolates.  From those, 20 isolates contained the class 1 integron, 6 
isolates had class 2, 1 isolate had both classes, and none of the isolates had the class 3 
integron.  Isolates positive for integrons had at least one resistance gene.  There was a 
significantly higher number of integron-positive E. coli isolates from pig farmers than 
from either Amerindians or bank-insurance workers.  Two of the 18 class 1 integrons 
had the dfr gene cassettes, 8 integrons had aadA, and 8 integrons had both gene 
cassettes.  Four of the class 2 integrons had dfr-1, sat, aadA, and orfX genes and 2 had 
sat, aadA, and orfX.   The authors suggested that the higher prevalence of E. coli isolates 
harboring integrons in pig farmers, as compared to the other 2 groups, was due to the 
farmers’ exposure to animals.  The prevalence of E. coli integron positive isolates was 
likely higher in the bank workers than Amerindians because of the higher probability of 
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exposure to antimicrobial agents in bank workers compared to Amerindians.  The higher 
prevalence of integrons in pig farmers could be a result of not only working with pigs, 
but also that they are more likely to be exposed to other animal species and antibiotics 
themselves (medicated feed) when compared to the other 2 groups.  Furthermore, the 
exposure to antimicrobial agents could be different in the 3 populations (work and living 
standard-related).   For example, the Amerindians group may have completely different 
exposures (at different risk of acquiring AR bacteria from animals and food as well as 
differences in their antimicrobial use) than the other 2 groups because of living in a 
developing region of French Guyana.   
2.4. Risk factor studies as related to antimicrobial resistance in animal agriculture 
Multiple studies have examined various antimicrobial use practices as they relate to 
levels of AR bacteria in food-producing animals at both the individual and the group-
level.  Collecting and presenting antimicrobial-use data in a ready-to-use format is 
difficult.  It requires collecting a huge amount of information on antimicrobial product 
used (amount and route of administration), number of animals treated, duration of use, 
and changes related to season (amount and type of antimicrobial, as well as illness in the 
animals) (Shryock, 1999).  However, antimicrobial use alone does not generally explain 
the spread and persistence of AR bacteria in animal populations where the antimicrobial 
use is discontinued or else is very limited.  Other risk factors such as antimicrobial 
residues in the environment (e.g., soil, water, wastewater, and lagoons), wild animals 
that shed and contaminate animal feed and water with AR bacteria, and AR gene 
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dissemination in different human and animal populations also have an impact on the AR 
levels on farms and consequently on the food chain (Kummerer, 2003). 
Mathew et al. (1999) have studied the relationship between multi-drug resistance 
patterns and the antimicrobial use, as well as pig age, on 10 swine farms in Tennessee.  
The farms were classified into low antimicrobial use (LOW, n = 3, if no subtherapeutic 
antibiotics or if tetracycline alone was used for short periods in subtherapeutic doses) 
and high antimicrobial use (HIGH, n = 7, routine use of subtherapeutic antibiotics in 
feed and/or injectable antibiotics).  Rectal swabs from 5 sows per farm in addition to 5 
rectal swabs from piglets per sow were collected.  Additional samples were collected 
from those sampled piglets at 35 and 63 days of age.  Escherichia coli were isolated on 
MacConkey agar, confirmed using biochemical analysis (API20), and then tested for 
antimicrobial susceptibility using the disk diffusion method for the following 
antimicrobial agents: apramycin, carbadox, gentamicin, neomycin, and oxytetracycline.  
The overall prevalence of multi-drug resistance was higher on HIGH farms than LOW 
farms across pig production sampling time points.  Among LOW farms, the incidence of 
multi-drug resistance in pigs across the production (i.e., growth) stages did not differ.  
However, E. coli multi-drug resistance was significantly (p < 0.001) higher for pigs 35 
days of age in HIGH farms compared to other pig production stages.  When the multi-
drug resistance profile included both neomycin and oxytetracycline, E. coli multi-drug 
resistance was highest at 63 days of age.  The authors have suggested that age was a risk 
factor affecting resistance levels in swine, mainly in nursery pigs where subtherapeutic 
antibiotic use is high.  The authors did not examine the effect of size of the farm (i.e., 
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number of pigs) on the multi-drug resistance.  Furthermore, the time variable was not 
controlled for in the analysis.  They could have utilized generalized linear models 
(GLM) and adjusted for farm or time dependency using a generalized estimating 
equation (GEE) for the multinomial outcome (multi-drug resistance).   
The relationship between prevalence of resistant E. coli and antimicrobial use at the 
group-level on 34 Canadian swine farms was assessed by Dunlop et al. (1998b).  The 34 
farrow-to-finish farms were classified into 4 groups: 1) farms with no antimicrobial 
supplementation in the post-weaning ration, 2) farms with antimicrobial agents 
supplemented to the weaning-pig ration, 3) farms with antimicrobial agents 
supplemented to the weaning-pig ration, and also supplemented with gram-positive 
antimicrobial agents in the grower-finisher ration, 4) same as (3) except that tetracycline 
was added to the grower-finisher ration instead of the gram-positive antimicrobial 
agents.  Fecal samples (n = 20) were collected from finisher pigs 1 month before 
slaughter on each of the study farms.  The E. coli isolation and susceptibility testing was 
described earlier in this chapter (see Dunlop et al., 1998a).  The prevalence of resistance 
to each antimicrobial agent was regressed on the antimicrobial use data at both the group 
and individual pig level.  Other risk factors in the study (e.g., farm size, farm 
management factor (e.g., number of sows, type of grower-finisher housing)) were 
controlled for by using logistic regression models.  In general, in-feed medicated rations 
were significantly associated with an increase in the prevalence of E. coli resistant to 
each antimicrobial agent in this study, when compared to individual therapeutic 
antimicrobial agents also used in pigs.  Tetracycline supplementation to the grower-
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finisher pigs was associated significantly with an increased prevalence of tetracycline 
resistant E. coli.  The prevalences of ampicillin, sulfisoxazole, and spectinomycin 
resistance to E. coli were significantly higher on farms with tetracycline supplementation 
in their grower-finisher pigs than on farms without this supplementation.  The addition 
of gram positive antimicrobial agents (typically, either tylosin or salinomycin) to the 
grower-finishers rations was associated with an increased prevalence of spectinomycin-
resistant E. coli.  The individual treatment of piglets with gentamicin (this agent was not 
used in the feed ration) was associated with a slightly increased prevalence of 
gentamicin-resistant E. coli in finisher pigs.  The prevalences of E. coli resistance to 
ampicillin, gentamicin, spectinomycin, sulfisoxazole, and tetracycline, in post-weaning 
pigs on the farms (n = 5) that had no antimicrobial use, were 7.1%, 1.0%, 16.9%, 24.0%, 
and 47.1%, respectively.  The authors concluded, on the basis of this study, that 
medicated feed rations in swine farms have a larger effect on increasing prevalence of 
resistance E. coli when compared to individual antimicrobial treatment.  In addition, they 
suggested that antimicrobial use on swine farms was associated with an increased level 
of E. coli resistance in finisher pigs.  The authors could have sampled the finisher pigs in 
the slaughter-house lairage pens to assess the AR bacteria levels right before slaughter, 
and compared them to finisher pigs.  They also could have sampled other swine 
production groups (e.g., piglets, nursery, and growers) to compare resistance levels to 
finishing pigs.   
The prevalence of AR Salmonella and other AR Gram-negative fecal bacteria was 
compared between grower-finisher pigs that had medicated feed (subtherapeutic levels 
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of tetracycline) and those that had non-medicated feed (Funk et al., 2006).  In their field 
trial, 3 swine farms were selected (convenience sampling).  Selected barns (n = 22) 
within each farm containing pigs 10 – 24 weeks of age received treatment 
(subtherapeutic tetracycline), while pigs in other barns received no treatment.  Individual 
fecal samples (n = 96) were collected per rectum from finisher pigs at each barn, 
cultured for Salmonella and other Gram-negative fecal bacteria, and tested for 
antimicrobial susceptibility.  All Salmonella positive isolates 0.7% (n = 15, out of 2112 
cultured fecal samples) were susceptible to amikacin, ciprofloxacin, and nalidixic acid.  
However, they were variably resistant to amoxicillin/clavulanic acid, ampicillin, 
cefoxitin, ceftiofur, cephalothin, chloramphenicol, streptomycin, sulfisoxazole, 
tetracycline, and trimethoprim/sulfamethoxazole.  There were 76,521 fecal Gram-
negative isolates obtained from 846 pigs in 22 barns.  These isolates were tested for 
susceptibility to 4 antimicrobial agents: ampicillin, ceftiofur, gentamicin, and 
tetracycline.  Resistance to tetracycline and ceftriaxone were reported in 97.5% and 
0.7% of all the isolates from treated pigs, versus 84.3% and 0.3% from the non-treated, 
respectively.  There was a significant association between the prevalence of fecal Gram-
negative resistance to ampicillin (OR = 1.35), tetracycline (OR = 7.2), and ceftriaxone 
(OR = 2.36) and being one of the treated pigs, when compared to being untreated.  
However, the authors did not control for the actual individual pig treatments (e.g., 
ceftiofur) in the statistical models, which may further bias the ceftriaxone resistance 
levels. 
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Langlois et al. (1988) examined the relationship between AR fecal coliforms 
isolated from antibiotic-free pigs and 2 risk factors (age and housing type).  The study 
population consisted of pigs in a single herd that had not been exposed to antibiotics for 
126 months.  The herd was composed of gestation gilts and sows (which were housed on 
pasture), as well as farrowing and finisher pigs that were housed in pens.  Over a 20-
month period, at 12 separate occasions, individual pig fecal samples were randomly 
collected per rectum by production stage in order to represent various age groups.  Pig 
age groups were later classified for analytical purposes into: weaning (≤ 2 months), 
growers (2 – 6 month), developing (> 6 – 11 months), young adults (>11 – 24 months), 
and adult pigs (> 24 months).  Fecal coliforms (n = 2,072) were isolated from the 
samples on MacConkey agar and 5 colonies per plate were tested for antimicrobial 
susceptibility to 13 antimicrobial agents using the disk diffusion method.  The greatest 
percentages of fecal coliforms resistant to tetracycline (68%), sulfisoxazole (44.5%) and 
streptomycin (29.7%) were in weaning pigs, while ampicillin (13%) resistance was 
greatest in the growers.  The fecal coliform resistance prevalences of tetracycline, 
sulfisoxazole, streptomycin, and kanamycin as well as multidrug resistance to 2 or more 
antimicrobial agents were significantly (p < 0.05) higher in weaning pigs compared to 
the other swine age groups.  However, ampicillin resistance prevalence was significantly 
(p < 0.05) higher in the growers.  In general, the authors indicated that resistance levels 
in fecal coliforms decreased as the pigs aged in an antibiotic-free herd.  The prevalences 
of ampicillin and tetracycline fecal coliforms were significantly (p < 0.05) higher in 
finisher pens compared to farrowing pens and pasture, while sulfisoxazole resistance 
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was higher in farrowing pens compared to finishers and on-pasture pigs.  The overall 
highest fecal coliform resistance was to tetracycline (63.5%).  The authors concluded 
that there must be other risk factors that contributed to the increase and persistence of 
resistance levels in fecal coliforms in pigs beyond current antimicrobial use.  In this 
study, the authors did not account for the effect of density (e.g., number of pigs per 
square meter in the pen) or the effect of mixing behavior (contact rate) among different 
age groups on the fecal coliform AR levels.  Moreover, there was no information 
collected regarding the pigs that may have been introduced or imported into the herd.  
Imported pigs may carry and shed more AR bacteria and thus may be more likely to 
disseminate AR bacteria to other pigs in the herd.  Furthermore, since sampling was 
performed over a 20-month period, the authors should have also examined the resistance 
level in relation to seasonal (time) changes.   
The AR bacteria levels were assessed in 2 non-antibiotic exposed small rodent 
populations (2 different species) in England (Gilliver et al., 1999).  The first population 
(n = 38) was close to woodlands, gardens and a lake, while the second population (n = 
70) was nearby to pastures where heifers were usually kept.  Fecal droppings were 
collected, microbiologically cultured, and bacterial isolates were tested for antimicrobial 
susceptibility.  Overall, high resistance levels (90% of the isolates) to amoxicillin, 
amoxicillin/clavulanic acid, and cefuroxime were reported.  Depending on the bacterial 
species, 14-76% of coliforms were resistance to tetracycline, 0-67% to trimethoprim, 
and sensitive to chloramphenicol.  The authors suggested that the level of AR fecal 
coliforms in the wild rodents was a source of resistant bacteria that disseminated to 
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livestock through contaminated pasture, feed and water.  Interestingly, the authors did 
not assess the exposure of wild rodents to contaminated food and water with AR bacteria 
to determine the source of resistance.  Also, the mixing effect of susceptible and resistant 
(AR bacteria carrier) rodents was not evaluated.  This was a one-time point sampling 
(cross-sectional) study where cause and effect could not be established.  Thus, without 
studying the temporal variability in the fecal coliforms resistance levels, the study 
conclusions should be interpreted with caution.   
The proportion of AR Salmonella isolated from dairy farms as related to risk factors 
(antibiotic use on conventional vs. organic farms, herd size, and the U.S. state in which 
farms were located) was assessed by Ray et al. (2006).  Fecal (n = 24,762) and 
environmental (n = 5,056) samples were collected from organic (n = 26) and 
conventional (n = 69) dairy farms from 4 states, with herds containing at least 30 
milking cows.  Organic farms had very limited or no antimicrobial usage for at least 3 
years prior to the sample collection.  The collection period started in August 2000 and 
ended in October 2001.  Conventional farms typically had both therapeutic and 
subtherapeutic antimicrobial use.  The number of fecal samples (i.e., sample size) was 
proportional to the size of the herd and represented: 1) preweaned calves that were fed 
medicated and non-medicated milk replacers, 2) cows after calving, 3) cows to be culled, 
and 4) sick cows.  Environmental samples were collected from different parts of the 
dairy farms (e.g., calving and sick pen floors, feed bunks, lagoons, bird droppings, bulk 
tank milk and milk pipe filters).  Samples were cultured for Salmonella and these 
isolates (n = 1243) were tested for antimicrobial susceptibility to 14 antimicrobial agents 
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using a broth microdilution method.  The MIC values were reported and interpreted 
according to NCCLS (1999).  Isolates that showed resistance to 4 or more antimicrobial 
agents were classified as multi-drug resistant.  The relationship between the proportion 
of AR Salmonella farms or herds (farms were classified as having resistance if at least 1 
isolate was resistant to one antimicrobial agent) and the risk factors for each 
antimicrobial agent were assessed using logistic regression and proportional hazards 
(PH) models (farm-level analysis).  In the PH model, if at least one isolate for each 
antimicrobial agent from each farm had an MIC value equal to the highest MIC value 
tested, then the farm was considered right censored.  In general, there were greater 
proportions of resistant isolates to most of the individual antimicrobial agents, as well as 
multi-drug resistance, from the conventional farms when compared to the organic farms, 
except for amoxicillin/clavulanic acid, nalidixic acid, and 
trimethoprim/sulfamethoxazole.  However, the last 2 antimicrobial agents had only a 
single resistant isolate in each farm type.  There was significantly higher resistance only 
to streptomycin among conventional farms when compared to organic farms using the 
logistic regression model.  Similarly significant associations were reported for 
streptomycin and sulfamethoxazole but this time based on the PH model.  Herd size was 
significantly (p < 0.05) associated with an increase risk of resistance for both types of 
farm for: amoxicillin/clavulanic acid, ampicillin, ceftiofur, cephalothin, 
chloramphenicol, gentamicin, streptomycin, sulfamethoxazole, and tetracycline. The 
association between herd-level multi-drug resistance isolates and the various risk factors 
was not significant (p > 0.05).  The authors suggested that, based on the lack of 
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significant differences in resistance proportions for almost all the antimicrobial agents 
tested between both type of farms (conventional and organic), that on-farm antibiotic use 
was not the only factor driving resistance levels in dairy farms.  The authors did not 
examine the differences in the AR prevalence in the study cohorts within farms in their 
analysis; for example, to examine whether the pre-weaned calves AR Salmonella 
prevalence was different when compared to sick or culled cows.  The authors could have 
performed the analysis differently by applying a multi-level hierarchal model (state, 
farm, herd, and cattle cohort or cattle environment sample) using, for instance, 
generalized linear latent and mixed models (GLLAMM) to adjust for the dependence in 
the data (data were collected at the individual cattle level, and thereafter aggregated as 
described above).  Also, in this study the authors collected environment samples, but did 
not assess the effect of the isolated AR Salmonella on the resistance levels on the study 
dairy farms and how they were related to antimicrobial use on farm. 
2.5  Summary of the literature review 
 Antimicrobial resistance studies have largely been aimed at examining the 
relationship between AR bacteria levels (or AR genes (proportion or quantity)) in 
humans and animals and a variety of potential risk factors.  The risk factors were 
generally: antimicrobial use (therapeutic and subtherapeutic), farm size, housing, animal 
species, stage of production, and environment.  Most of the studies based their findings 
on the commonality of resistance phenotypes, genotypes, or both, among specific 
commensal or pathogenic AR bacteria.  None of the studies controlled for their study 
subjects’ exposure to extraneous sources of AR bacteria (e.g., animal species other than 
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the study subjects, food from unknown sources, contaminated water) that could 
potentially bias the study results.  Also, and to the best of our knowledge, there have 
been no studies that addressed the AR transmission risk among human and animal 
populations longitudinally and in a “controlled” semi-closed agri-food system.  
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CHAPTER III 
MATERIALS AD METHODS 
3.1.    Study design  
Our study agri-food system consisted of multi-site housing of vertically integrated 
populations of human workers and consumers, and swine.  Humans were housed in 19 
purposively chosen and separate geographical locations (units) across the state of Texas.  
Twelve of these units had swine operations.   
3.1.1. Human population 
The human population consisted of a total of approximately 39,000 male individuals 
spread over the 19 units.  Based on occupational exposure (i.e., vocation) to swine and 
other factors, these individuals were classified as either swine workers, non-swine 
workers, swine slaughter-plant workers, or non-swine workers and non-consumers, 
based on the opportunity to consume the pork produced within the system.  There were 
12 units where both swine workers and non-workers resided, 6 units with only non-
swine workers, and only 1 unit with a swine slaughter-plant facility (Fig. 1, A-D). 
Approximately 86% of the human population consisted of non-swine workers.  
There also existed a non-consumer and non-worker cohort, which resided outside the 
agri-food system (at some of the units); this cohort was sampled in order to represent the 
general population as a ‘negative control’ group.  There was moderate movement of 
‘new residents’ into the system via a centralized unit, but restricted movement out of the 
system (Fig. 2).  
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3.1.2. Swine population 
The swine population consisted of approximately 26,000 – 28,000 pigs during any 
given month, located across 12 operations.  These operations were comprised of 5 
farrow-to-finish swine facilities, and 8 additional grower-to-finisher facilities.  There 
were occasional (i.e., roughly every 4 months) movements of pigs into the system 
(purchased purebred and mixed breed boars) into a single quarantine swine operation 
where pigs were held for 4 weeks prior moving to other operations.  In addition, there 
were outside gilts introduced into the system during the study period.  However, there 
was little or no movement out of the system since all the pigs were slaughtered and 
consumed within the system, except for very minor numbers of slow-growing swine.  
The swine population flowed vertically through farrow-to-finish units (farrowing 
barns to the hot nursery, to the cold nursery, to grower, and last to finisher barns) or to 
grower-to-finisher units, then sent to slaughter where pork products were processed and 
fed back (consumed) to the human population within the system (Fig. 3).  When pigs 
arrived at the slaughter plant, they were held in holding pens overnight before they were 
slaughtered.  For the purpose of data analysis, the swine population was categorized into 
7 production groups: 1) farrowing crate pigs (included farrowing sows and their piglets), 
2) nursery piglets (included both hot and cold nursery piglets), 3) breeding/gestation 
females (included breeding gilts, pregnant sows and gilts), 4) breeding boars, 5) isolation 
boars (boars at the quarantine facility), 6) grower-to-finisher pigs, and 7) slaughtered 
pigs (pigs at the holding pens).
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3.2.  Sampling scheme 
3.2.1. Human population 
Multiple composite wastewater grab samples (approximately 50 ml each) were 
collected from all 19 human units.  Those samples were collected monthly over a period 
of 36 months (February 2004 – January 2007) by trained personnel at each unit location.  
Typically, at each unit with a swine operation, 3 swine-worker wastewater (manhole) 
samples (consumers), 3 non-swine worker (both consumers, and non-consumers) 
wastewater (manhole) samples, and 1 mixed influent (draining from both of the groups) 
sample were collected.  At those units without a swine operation, 4 wastewater samples 
(3 non-swine workers (both consumers, and non-consumers) from manholes and 1 
mixed influent sample were collected.  At the single unit with a slaughter-plant, 7 
wastewater samples were collected, representing 3 non-worker manholes (consumers), 3 
slaughter-plant worker manholes (consumers), and 1 mixed influent.  The specific 
sampling locations were chosen purposively to differentiate the occupational human 
cohorts (swine-workers (consumers), non-swine workers (consumers), slaughter-plant 
workers (consumers), and the non-worker, non-consumer cohorts.  Typically, the 
number of wastewater samples collected per month was 116.  Sample pick-up and 
shipping from each unit was performed by a privately licensed and contracted agency.  
Samples were shipped to the USDA-ARS-Southern Plains Agricultural Research Center 
(USDA-ARS-SPARC) (College Station, Texas) for further analysis. 
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3.2.2. Swine population 
Composite fresh fecal floor samples (approximately 50 g each) and barn-wash/pre-
lagoon influent samples (approximately 50 ml) were collected from the 12 swine 
operation pens and the slaughter-plant holding pens by a swine specialist veterinarian.  
Those samples were likewise collected monthly for a period of 36 months (January 2004 
– December 2006).  Samples were kept at 4ºC overnight until they were shipped to the 
USDA-ARS-SPARC laboratory.  To effectively sample all of the swine pens, a tri-
monthly sampling scheme was carried out to sample different pen areas of the same 
swine facility each month.   
A composite fecal sample (50 g) was composed of equal portions of fecal pats from 
multiple pens.  Barn-wash/pre-lagoon samples were obtained from certain collection 
points that drained off the fecal sampled pens.   The collected samples at each farm 
represented the different swine production groups described earlier.  Furthermore, 
composite fecal samples from the slaughter-plant holding pens, kill floor influents, and 
pork trim samples from the slaughter-plant unit also were collected.  Approximately one-
third of the total pork consumed by the human population was from imported pork trim 
(personal communication with swine specialist veterinarian).  Grab samples were 
collected from each of these imports (pork trim) and evaluated for AR E. coli isolates. 
Typically, the total number (from all locations) of composite fecal samples per 
month was 140, and the number of barn-wash/pre-lagoon influent samples was 35.  The 
number of monthly swine samples was variable over the study period due to changes in 
the number of pigs at different production stages in the operations over the study period.  
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3.3. Phenotypic analysis of antimicrobial resistance  
3.3.1. Microbiological isolation of E. coli 
Upon arrival at the laboratory, 5 aliquots of each of the human and swine samples 
were frozen at -72ºC both without (n=2), and with (n=3), glycerol at a ratio of 3:1 
(sample: glycerol) for later analysis.  At the time of microbiological analysis, frozen 
human wastewater samples were thawed completely, vortexed or mixed with a sterile 
loop, and then a 1-ml aliquot of wastewater sample was added to 9 ml of tryptic soy 
broth (TSB) (Becton, Dickinson and Company, Sparks, MD)) for enrichment.  This 
mixture was then incubated for 18 hr at 37ºC, streaked onto a selective medium of 
CHROM agar-E. coli™ (DRG International, Mountainside, NJ) and incubated further at 
37ºC for 18-24 hours.  No enrichment step was used when swine fecal samples were 
cultured (i.e., directly streaked onto CHROM agar).  For pork, approximately 5 g was 
dissected out of the pork trim sample, mixed for 1 minute in a stomacher with peptone 
water (10-ml), and then streaked with a sterile loop onto CHROM agar as described 
above.   
A single typical E. coli colony (blue color with smooth surface) was randomly 
selected, streaked onto a blood agar plate, and then incubated (18 hr, 37ºC).  Based on a 
pilot study for this research project (Scott et al., 2005), CHROM agar-E.coli™ selective 
media was noted to be highly specific and yielded >98% E. coli colonies.  Furthermore, 
a biochemical test strip (API 20E, BioMerieux Inc.) was used regularly as quality control 
to confirm the isolates as E. coli.  Escherichia coli isolates were transferred onto 
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glycerol coated beads (Key Scientific, Round rock, TX) and stored at -72ºC for future 
retrospective analyses.  
3.3.2. Determination of antimicrobial susceptibility for E. coli isolates 
A typical E. coli isolate was picked from the blood agar as described earlier, and the 
minimum inhibitory concentration (MIC) was determined for different antimicrobial 
agents by broth microdilution (CDC, 2003) using the Sensititre
TM
 automated system 
according to the manufacturer’s instructions (Trek Diagnostic Systems, Cleveland, OH).  
The MIC values were interpreted as either resistant or susceptible (which included 
intermediate MIC classifications) based on NCCLS break points (1999).  To assess the 
variable number of different resistant phenotypes in the samples, 5 E. coli colonies were 
selected randomly from human and swine samples during one month only (February, 
2005).  The mean number of different phenotypes for human and swine for that month 
were 2.25 and 1.98 (out of 5), respectively and the median was 2 for both human and 
swine.  The antimicrobial agents that were used in the NARMS (2003) panels and their 
break points are provided in Table 1.  Quality control (QC) organisms from the 
American Type Culture Collection (ATCC, Manassas, VA) strains E. coli 25922 and 
35218, Enterococcus faecalis 51299, and Pseudomonas aeruginosa 27853 were 
evaluated on approximately every 200 NARMS custom panels, or with each new serial 
numbered batch,  used in the laboratory to ensure panel laboratory quality.  
3.3.3. Sample phenotypic analysis scheme 
Samples were analyzed on a quarterly basis over the 3-year study period.  All human 
(n = 1241) and swine (n = 1847) samples collected during the first 12 months of the  
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study were phenotypically analyzed.  These data were later collapsed into 4 seasons (or 
quarters) based on: 1) winter: February – April, 2) spring: May – July, 3) summer: 
August – October, and 4) autumn: November – January).  Thereafter, only quarterly 
phenotypic analysis was performed on the other 24 months of sampling (human, n = 
812, and swine, n = 1303).  Quarterly sampling and analysis was conducted because the 
highest variability was observed between seasons as compared to between months within 
season based on the first 12 months of data analysis.  
3.4. Genotypic analysis 
3.4.1. Total community D5A extraction 
Total community DNA was extracted from diluted swine fecal matter, and from 
concentrated human wastewater samples, using the UltraClean
TM
 Fecal and Soil DNA 
kits (Mo Bio
®
, Solana Beach, CA), respectively, according to the manufacturer’s 
instructions.  Glycerol-free samples were thawed completely at room temperature before 
extraction was performed.  Extracted community DNA samples (~50 µl) were kept at -
20ºC. 
3.4.2. Antimicrobial resistance gene quantification using real-time PCR (qPCR) 
Absolute quantification is based on comparison of an unknown sample to a standard 
dilution series with predetermined and known concentrations of a gene.  The resulting 
amplification plots from the samples of unknown concentration are compared to the 
results from the standard curve and the number of the target gene copies is estimated 
from the curve (Wittwer and Kusukawa, 2004).  In our study, the target gene was b-
lactamase cephamycins resistance (blaCMY-2) and the house-keeping (i.e., reference) gene 
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for standardizing the sample-to-sample variation in bacterial content was the RNA 
polymerase beta subunit (rpoB).  
The target gene was quantified using the following 3 steps: 1) real-time PCR 
amplification to create PCR-products (i.e., standard template) in order to build the 
standard curve, 2) nested real-time PCR amplification to build a standard curve from the 
PCR-products, and 3) Ct value determination (the cycle number at which the 
fluorescence intensity reaches a set cycle threshold value) for the amplified blaCMY-2 gene 
in the unknown total community DNA samples.  The sequence of the primers is shown 
in Table 2.  Fig. 4 shows a schematic of the blaCMY-2gene and the position of the primers 
used in this study.   
3.4.2.1.  Quantification standards (PCR product standard) 
An E. coli isolate that harbors a plasmid-mediated AmpC B-lactamases blaCMY-2 
gene (Odeh et al., 2002) was obtained from the University of Illinois, Chicago.  This 
isolate was streaked on sheep blood agar and incubated for 18 hours at 37ºC.  Total 
DNA was extracted from a randomly picked colony, then suspended in 500 ml of Sigma 
water (Sigma-Aldrich, St. Louis, Mo.), heated at 95ºC for 10 min to lyse the bacterial 
cell wall, centrifuged for 2 min to pellet the cell debris, and then the sample template 
was stored at -20ºC.
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The amplification targeted the blaCMY-2 gene using primers 585F and 1038R, 
producing 454-bp PCR products (i.e., amplicons).  The PCR reaction was performed on 
a total volume of 50 µl using the Brilliant
®
 SYBR
®
 Green qPCR Master Mix 
(Stratagene, La Jolla, CA) in a real-time PCR system (Stratagene Mx3000P
TM
, 
Stratagene, La Jolla, CA).  Each reaction included 25 µl 2 x SYBR Green qPCR master 
mix, 17.75 µl of Sigma water (Sigma-Aldrich, St. Louis, MO), 0.75 µl of each primer 
(2.7 µM), and 0.75 µl of the reference dye (30 nM).  The reaction conditions for 
amplification of DNA were 95ºC for 10 min, 35 cycles of 95ºC for 10 s, 55ºC for 45 s, 
and 84ºC for 20 s.  To determine the specificity of amplification, analysis of the product 
melting curve was performed after the last cycle.  A negative control was included in the 
run.  The PCR products were then loaded into 1% agarose gel electrophoresis to re-
confirm that only one product was synthesized per reaction.  The PCR products were 
purified (i.e., extracted) from the gel using QIAquick
®
 Gel Extraction Kit (Valencia, 
CA), quantified and checked for purity by a NanoDrop
®
 ND-1000 UV–Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE) at a wavelength of 260 
and 280 nm.  The concentration of DNA was calculated according to the formula ng 
DNA/µl = optical density at 260 nm × 50 × dilution factor and the number of PCR 
products was then calculated.   
Ten-fold serial dilutions were performed on the PCR-products and 10
6
, 10
5
, 10
4
, 10
3
, 
10
2
, and 10
1
 copies of the gene per reaction were used to construct the standard curve.  
The dilutions were performed in water first, then an aliquot from each dilution was 
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added to a wastewater, swine fecal matter total community DNA free of blaCMY-2 to act 
as a background matrix. 
3.4.2.2.  Standard curve methodology 
Amplification via nested PCR reactions was performed to generate a standard curve 
(gene copy numbers versus Ct values) using the prepared serial dilutions of the PCR-
products as described above.  The amplicon size was 64 bp using primers 675F and  
738R (see Fig. 4).  The PCR reaction was performed in triplicates on a total volume of 
50 µl using the Brilliant
®
 SYBR
®
 Green qPCR Master Mix (Stratagene, La Jolla, CA).   
 Each reaction included 25 µl 2 × SYBR Green qPCR master mix, 17.75 µl of Sigma 
water (Sigma-Aldrich, St. Louis, Mo.), 0.75 µl of each primer (2.5 µM), and 0.75 µl of 
the reference dye (30 nM).  The reaction conditions for amplification of DNA were 95ºC 
for 10 min, 40 cycles of 95ºC for 10 s, 52ºC for 30 s, and 79ºC for 17 s.  To determine 
the specificity of amplification, analysis of the product melting curve was performed 
after the last cycle.  Negative and positive controls were included in each real-time PCR 
run.  
3.4.2.3. Gene quantification in total community D5A samples 
The Ct value for the amplified blaCMY-2 gene sequence (62 bp obtained using the 
primers 675F and 738R) in the unknown community DNA samples was determined as 
follows.  The reaction mix and amplification conditions were the same as for the 
standard curve.  The gene copy numbers in the community DNA samples were 
determined based on the comparison of the obtained Ct values to the standard curve.  A 
standard curve was constructed with every real-time qPCR run aimed at quantifying the 
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target gene in the unknown community DNA samples.  The blaCMY-2 gene copy numbers 
per wastewater or fecal sample were then standardized using the reference gene (rpoB).  
The reference gene was also quantified using the same methodology as the target gene 
except for: 1) the primer sequences (see Table 2), 2) the concentration of each primer 
which was 2.8 µM and 2.3 µM for generating PCR-products and building the standard 
curve as well as determining the Ct in the community DNA samples, respectively, 3) the 
amplification reaction conditions which were: 95ºC for 10 min, 35 cycles of 95ºC for 15 
s, 55ºC for 60 s, 72ºC for 15 s for generating the PCR-products, and 95ºC for 10 min, 40 
cycles of 95ºC for 10 s, 53ºC for 30 s, 76ºC for 30 s for building the standard curve and 
determining the Ct value in the community DNA samples. 
3.4.3. Preliminary genotypic analysis 
Total community DNA extracted from human wastewater and swine fecal matter 
samples (n = 24) from the month of February 2004 were examined for blaCMY-2 and rpoB 
gene quantities.  These quantities were expressed in copies/µl and as a ratio (rpoB: 
blaCMY-2) using the qPCR method as described earlier.  The community DNA samples 
were selected to represent different human vocation cohorts and swine production 
groups in one sampling month.  Samples were run in triplicates along with standard 
curves.  
3.5. Statistical analysis 
3.5.1. Descriptive statistics 
 
The 15 antimicrobial resistance outcomes (binary) – as well as multi-drug resistance 
totals (multinomial) – were cross-tabulated with each of the risk factor categories: host 
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species (swine versus human), swine production type (e.g., breeding/gestation, breeding 
boars, farrowing, nursery, grower-finisher, isolation boar, slaughter holding pens), 
human vocation (swine worker versus non-worker), human consumer versus non-
consumer, and season.  Initially, the proportion of bacteria resistant to each of the 
antimicrobial agents was compared across levels of each risk factor using either two-
sided 2 × 2 Fisher’s exact test or 2 × n likelihood-ratio chi-square test, as appropriate, in 
STATA
TM
 ver. 9.2 (College Station, TX).  Multi-drug resistance was assessed for each 
risk factor similarly as the sum of resistance (out of 15 agents, upper (6+) categories 
were collapsed) across all isolates using an m × n likelihood-ratio chi-square test. 
3.5.2. Multivariable analysis of risk factors for E. coli resistance to individual 
antimicrobial agents 
The association between the AR E. coli isolate phenotypes and the risk factors in the 
study was assessed using a generalized linear model (GLM), with binomial error 
distribution, logit link function, and adjusted for dependency within unit location using 
generalized estimated equations (GEE) in STATA
TM 
ver 9.2.  GEE is a marginal (i.e., 
population-averaged) model that assumes that the relationship between the outcome 
(binary) and the predictors (risk factors) is the same for all subjects across clusters 
(Carriere and Bouyer, 2002; Dohoo et al., 2003; Hanley et al., 2003).  
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3.5.3. Multivariable analysis of risk factors for E. coli resistance to multiple 
antimicrobial agents  
The ordinal response (multi-drug resistance from 0 to 15 antimicrobial agents; 6+ 
collapsed into a single upper category) of E. coli phenotypes in relation to the risk 
factors was assessed using a GLM model, with a multinomial distribution and a  
cumulative logit link function, and adjusted for dependency using GEE within unit 
location in SAS
®
 ver 9.1 (PROC GENMOD, SAS Institute, Inc., Cary, NC). 
3.5.4. Multivariate analysis (dependence among multiple binary outcomes) 
3.5.4.1. Cluster analysis techniques approach 
Our objective was to assess the application of cluster analysis techniques, applied to 
an AR phenotype data set, by identifying clusters with similar (i.e., related) AR 
phenotypes in order to better describe the resistance patterns among bacterial isolates. 
The further objective of the analysis was to examine E. coli membership in the obtained 
clusters (ordered from low-to-high resistance clusters) in relation to the study risk 
factors. 
Antimicrobial resistance phenotypic data from the first season of longitudinal study 
were used to demonstrate and assess cluster analysis techniques.  The data set we 
worked with included 504 E. coli isolates that were obtained from human wastewater 
samples and were subsequently tested for antimicrobial susceptibility.  This data set 
contained outcomes for 15 antimicrobial agents on NARMS 2001 panels that included 
cephalothin and where amikacin was not considered in the analysis as the MIC values 
were not interpretable (Scott et al., 2005).  That is because the amikacin breakpoint fell 
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several dilutions beyond the range provided on the NARMS panels making the binary 
classification (susceptible or resistant) uninterpretable at ≥ 4.  
These data were in two forms:  1) ordinal data in the form of MIC values, and 2) 
binary scale (i.e., susceptible or resistant) which represented the dichotomized 
interpretation for 15 antimicrobial agents.   
Squared-Euclidean distance for dissimilarity was used for both types of data.  
Although squared Euclidean distance has been suggested to be most useful for 
continuous data (Everitt et al., 2001), we employed this measure using hierarchical 
methods on both types of outcomes (ordinal and binary data).  Cluster methods are 
typically descriptive, rather than analytical, and to use squared-Euclidean distance to 
classify the cases would be proper so long as it resulted in biologically meaningful 
clusters.   
Six hierarchical agglomerative clustering methods were applied to the E. coli 
phenotypes in order to determine their cluster memberships.  These methods were single 
linkage, complete linkage, average linkage, centroid linkage, median linkage, and 
Ward’s minimum variance.  Furthermore, the k-means method was applied to both types 
of data using the squared-Euclidean distance proximity measure.  The MIC values were 
used in three ways: 1) their original form, 2) standardized with a mean of 1 and a 
standard deviation of 1, and 3) natural log transformed.  The cluster analysis was 
performed using SAS
®
 ver. 9.1 (SAS Institute, Cary, NC) and SPSS
®
 (for Windows ver. 
12.0.1, SPSS Inc., Chicago, IL).  
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Cluster analyses typically provide more than one cluster solution.  Therefore, to 
obtain the best solution (aiming for parsimony), we attempted to minimize the within-
cluster variability, maximize between-cluster variability, all the while keeping the 
number of clusters to a minimum.  In addition, we paid particular attention to whether 
the clusters’ memberships reflected the underlying biological relationship among 
resistance phenotypes (i.e., many of the antimicrobial agents are of the same class). 
The final number of clusters in SAS
®
 was determined using the squared multiple 
correlation (R
2
), cubic clustering criterion (CCC) (Sarle, 1983), Pseudo-F (Calinski and 
Harabasz, 1974), and pseudo-T
2
 (PST2) (Duda and Hart, 1973) statistics.  R
2
, which is 
the proportion of variance accounted for by the clusters, was evaluated and plotted in a 
dendogram.  The CCC is calculated by looking at the difference between the observed 
and expected R
2
.  Values of CCC greater than 2 or 3 indicate good clusters (i.e., clusters 
are well separated); values between 0 and 2 indicate probable clusters and require further 
inspection, and large negative values may indicate outliers that should be removed 
before clustering is reattempted.  Pseudo-F and pseudo-T
2 
statistics indicate possible 
point(s) suggesting the appropriate number of clusters.   
At each stage of clustering, minimum within cluster sum of squares (WCSS), 
maximum between cluster sum of squares (BCSS) and variance ratio criterion (VRC) 
[i.e., pseudo-F] are calculated as: 
   
kn
WCSS
k
BSCC
VRC
−−
= /
1
       (1) 
 k= number of clusters; n = number of cases. 
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Therefore, based on these calculations for different k, it is recommended to choose 
the value of k that has absolute or local maximum.  In other words, choose the first value 
of pseudo-F from a monotonic decreasing series (Calinski and Harabasz, 1974).  The 
ratio index (2) proposed by Duda and Hart (1973) can be transformed into the pseudo-T
2
 
statistic.   
We then looked for the number of clusters that could be identified by a small value 
of pseudo-T
2
 that was immediately followed by a large value.   
 
)1(
)2(
e
e
J
J
         (2) 
 Je(2) is the within cluster sum of squares error when data are split into two clusters.  
Je(1) is the sum of square error before splitting the data.  If Je(2) < Je(1), then the one 
cluster hypothesis is rejected in favor of the two cluster solution.  
3.5.4.2. Multivariate model of correlated dependence 
The multiple binary AR outcomes (n = 15) for E. coli isolates were simultaneously 
assessed in relation to the risk factors using a GEE model fitted in a multivariate model 
using a SAS
®
 macro to adjust for dependence among resistance phenotypes and 
dependence within unit location.  This SAS
®
 macro was adapted from Shelton et al. 
(2004) and modified to perform the analysis on our data.  Briefly, the macro accounts for 
the correlations (i.e., dependence) among the binary outcomes in relation to each 
covariate (i.e., predictor).  The macro creates an outcome vector matrix (NY × 1), design 
matrix (NY × CN) to allow separate covariate effects for each of the correlated AR 
phenotypes, and a vector matrix for the covariate effects (C × 1); where N = number of 
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observations, Y = number of outcomes, and C = number of covariates.  These formed 
matrices are stored into a new dataset which is then used in SAS PROC GENMOD to fit 
the multivariate GEE model. 
The antimicrobial agent odds-ratios (unadjusted versus adjusted for dependence 
among resistance phenotypes) were examined for: 1) host species (swine versus human 
(referent)), and 2) human swine workers, isolation boars, breeding boars, farrowing sows 
and piglets, breeding/gestation females, grower-finisher pigs, and nursery pigs, as 
compared to the human non-worker cohort (referent). 
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CHAPTER IV 
RESULTS 
4.1.  Descriptive statistics 
There were 5559 (2130 human and 3429 swine) commensal E. coli isolates that 
arose from the wastewater and fecal matter samples over the 3-year study period.  Due to 
scheduling conflicts, not all units were sampled for wastewater collection every month.  
The total number of human wastewater and swine fecal samples collected, the number of 
isolates retained and tested for antimicrobial susceptibility by unit over the 3-year 
period, as well as the proportion of the isolates cultivated relative to the number of 
samples collected is shown in the tables on pages 76 and 78.  The 15 antimicrobial 
resistance outcomes (binary: susceptible or resistant) for E. coli isolates were cross-
tabulated first by host species and by unit as shown in the table on page 80.  The 
proportion of resistant bacteria among human isolates across the 19 units differed 
significantly (p < 0.05) for the following antimicrobial agents: ampicillin (p = 0.029), 
chloramphenicol (p = 0.023), ciprofloxacin (p = 0.008), nalidixic acid (p < 0.001), 
streptomycin (p = 0.021), and tetracycline (p < 0.001).  The proportion of resistant 
bacteria among swine isolates across only those 12 units with swine operations and the 
slaughter-house pigs differed significantly (p < 0.05) for the following antimicrobial 
agents: amoxicillin/clavulanic acid (p < 0.001), ampicillin (p < 0.001), cefoxitin (p < 
0.001), chloramphenicol (p < 0.001), gentamicin (p < 0.001), kanamycin (p < 0.001), 
streptomycin (p < 0.001), sulfisoxazole (p < 0.001), and tetracycline (p<0.001).  Next, 
the phenotypes were cross-tabulated by human vocation cohort (i.e., non-workers and 
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non-consumers, swine workers, non-swine workers, influent mixture, slaughter-plant 
workers) as shown in the table on page 84.  Only tetracycline resistance differed 
significantly (p = 0.025) among human exposure (i.e., vocation) cohort isolates with the 
highest prevalence found in slaughter-plant workers (25.9%), versus swine-workers 
(23.1%), non-swine-workers (17.6%), non-workers and non-consumers (14.3%), and 
influent mixture (22.8%).  The same approach was used to cross-tabulate by swine 
production group (i.e., slaughter-plant holding pens (slaughtered pigs), breeding boars, 
isolation/quarantine boars, breeding sows, farrowing sows and piglets, growers and 
finishers, and nursery piglets) as shown in the table on page 86.  In general, the isolation 
(i.e., purchased) boars showed higher levels of resistance (p < 0.001) than swine-rearing 
and slaughtered pigs for the following antimicrobial agents: ampicillin, chloramphenicol, 
kanamycin, sulfisoxazole, and tetracycline.  In contrast, nursery piglets showed higher 
level of resistance (p < 0.001) than isolation boars, other swine-rearing and slaughtered 
pigs for the following antimicrobial agents: cefoxitin, ceftiofur, gentamicin, and 
streptomycin.  There were 12 E. coli bacteria isolated from the 160 (7.5%) pork trim 
samples, 11 of which were resistance to at least 1 antimicrobial agent.  Among these, the 
frequency of multi-resistance phenotypes were as follows: pansusceptible (n = 1), single-
resistant (n = 4), and resistant to 3 antimicrobial agents (n = 7), with the most common 
phenotypes being: tetracycline and ampicillin-streptomycin- tetracycline.  Results were 
also cross-tabulated by consecutive seasons (winter, spring, summer, and autumn) 
throughout the 3-year period as shown in the table on page 87 and season-collapsed 
(winter, spring, summer, and autumn) over the 3-year period as shown in 
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Table 6   
 
Phenotypic resistance of commensal E. coli isolates from human wastewater samples (n 
= 2130 isolates with vocation cohort properly identified).  Frequencies and proportions 
are contrasted by human vocation cohort (i.e., non-workers and non-consumers, swine 
worker, non-swine worker, slaughter-plant worker, influent mixture) across all unit 
locations and seasons. 
 
Human vocation cohort  
Frequency of resistant E. coli isolates (%) 
 
 
Antimicrobial 
Non-worker, 
non-consumer  
isolates (n=77) 
Swine-worker 
isolates  
(n=536) 
Non-swine 
worker isolates 
(n=1084) 
Slaugher-plant 
workers 
isolates 
(n=58) 
Influent (mixed 
isolates  
(n=232) 
 
 
p-value
a
 
Amikacin 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
Amoxicillin 
/Clavulanic Acid 
1 (1.3) 14 (2.6) 28 (2.6) 2 (3.5) 5 (2.2) 0.922 
Ampicillin 15 (19.5) 85 (15.9) 180 (16.6) 5 (8.6) 38 (16.4) 0.459 
Cefoxitin 3 (3.9) 10 (1.9) 27 (2.5) 1 (1.7) 6 (2.6) 0.824 
Ceftiofur 0 (0.0) 3 (0.6) 2 (0.2) 0 (0.0) 0 (0.0) 0.468 
Ceftriaxone 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
Chloramphenicol 1 (1.3) 15 (2.8) 19 (1.8) 1 (1.7) 2 (0.9) 0.404 
Ciprofloxacin 1 (1.3) 5 (0.8) 9 (0.8) 0 (0.0) 0 (0.0) 0.294 
Gentamicin 0 (0.0) 2 (0.4) 6 (0.5) 0 (0.0) 0 (0.0) 0.474 
Kanamycin 2 (2.6) 7 (1.3) 17 (1.6) 0 (0.0) 0 (0.0) 0.063 
Nalidixic Acid 1 (1.3) 37 (6.9) 58 (5.4) 1 (1.7) 13 (5.6) 0.099 
Streptomycin 7 (9.1) 57 (10.6) 97 (9.0) 2 (3.4) 21 (9.1) 0.367 
Sulfisoxazole 8 (10.4) 68 (12.7) 179 (16.5) 6 (10.3) 30 (12.9) 0.126 
Tetracycline 11 (14.3) 124 (23.1) 191 (17.6) 15 (25.9) 53 (22.8) 0.025 
Trimethoprim / 
Sulfamethoxazole 
3 (3.9) 42 (7.8) 85 (7.8) 4 (6.9) 12 (5.2) 0.409 
a 
p-values are based on a likelihood ratio chi-square test of the differences in risk 
between human vocation cohorts.  These p-values are not adjusted for the dependence of 
responses within unit locations. 
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Table 9.  High variability was observed among seasonal samples over the 3-year period 
for both human and swine isolates across all units. 
Sixty-two percent of the human E. coli isolates were pan-susceptible to the 15 
antimicrobial agents on the NARMS panel, 20% were single-resistant, and 18% were 
resistant to 2 or more antimicrobial agents.  In contrast, only 13% of the swine E. coli 
isolates were pan-susceptible, whereas 42% were single-resistant, and 45% were 
resistant to 2 or more antimicrobial agents (see table on page 97).  The distribution of 
multi-drug resistant phenotypes (upper (6+) categories was not collapsed in Fig. 5 in 
order to show the maximum multi-drug resistance phenotypes for E. coli isolates from 
human and swine samples.  The multi-drug resistance (multinomial) phenotypes for E. 
coli isolates were cross-tabulated first by season (winter, spring, summer, and autumn 
across all 3 years) and host species as shown in the table on page 99 and then season 
collapsed (winter, spring, summer, and autumn) over the 3-year period as shown in the 
table on page 101.  The multi-drug resistant E. coli isolates from human samples differed 
significantly (χ
2 
= 189.6, p < 0.001) among seasons across all levels of multi-resistance.  
Likewise, the multi-drug resistant E. coli isolates from swine samples differed 
significantly (χ
2
 = 206.3, p < 0.001) among seasons across all levels of multi-resistance.  
High variability was observed among seasonal samples for multi-drug resistance 
phenotypes collapsed over the 3-year period for both human and swine samples.   
Multi-level resistance, cross-tabulated by human vocation cohorts and swine 
production groups, is shown in the table on page 103, where: a) isolation boars showed 
the highest levels of resistance to multiple antimicrobial agents (1.21%) relative to  
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Table 9 
Phenotypic resistance of commensal E. coli isolates from human and swine fecal 
samples.  Frequencies are contrasted by host species and seasons-collapsed over 3 years.  
Isolate comparisons are across all unit locations, human vocation cohorts and swine 
production groups. 
 
Sampled by season-collapsed
a
 (n=5559 overall 
sample isolates)  
Frequency of resistant E. coli  (%)  
Antimicrobial 
agent 
Host 
Species 
(S=Swine, 
H=Human) Winter Spring Summer  Autumn   
 
p-value
b
 
0 0 0 0 
H 
(n=2130)   (0.00) (0.00) (0.00) (0.00) - 
3 0 0 1 
 
 
 
Amikacin 
S 
(n=3429) (0.25) (0.00) (0.00) (0.14) 0.172 
15 17 10 12 
H 
(n=2130)  (1.98) (3.62) (2.71) (2.71) 0.347 
28 16 19 14 
 
 
Amoxicillin 
/Clavulanic Acid 
S 
(n=3429) (2.35) (2.16) (2.41) (1.98) 0.938 
144 60 62 79 
H 
(n=2130)  (19.00) (12.77) (13.48) (17.87) 0.007 
206 132 216 135 
 
 
 
Ampicillin 
S 
(n=3429) (17.27) (17.81) (27.41) (19.09) (<0.001) 
15 16 9 9 
H 
(n=2130)  (1.98) (3.40) (1.96) (2.04) 0.393 
24 16 14 12 
 
 
 
Cefoxitin 
S 
(n=3429) (2.01) (2.16) (2.16) (1.70) 0.911 
6 1 0 0 
H 
(n=2130)  (0.79) (0.21) (0.00) (0.00) 0.021 
22 27 17 17 
 
 
 
Ceftiofur 
S 
(n=3429) (1.84) (3.64) (2.16) (2.40) 0.105 
0 0 0 0 
H 
(n=2130)  (0.00) (0.00) (0.00) (0.00) - 
0 0 1 1 
 
 
 
Ceftriaxone 
S 
(n=3429) (0.00) (0.00) (0.13) (0.14) 0.344 
19 5 5 11 
H 
(n=2130)  (2.51) (1.06) (1.09) (2.49) 0.106 
49 24 47 29 
 
 
 
Chloramphenicol 
S 
(n=3429) (4.11) (3.24) (5.96) (4.10) 0.068 
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Table 9 (Continued) 
Sampled by season-collapsed
a
 (n=5559 overall 
sample isolates)  
Frequency of resistant E. coli  (%)  
Antimicrobial 
agent 
Host 
Species 
(S=Swine, 
H=Human) Winter Spring Summer  Autumn   
 
p-value
b
 
9 2 2 2 
H 
(n=2130)   (1.19) (0.43) (0.43) (0.45) 0.294 
1 0 0 0 
 
 
 
Ciprofloxacin 
S 
(n=3429) (0.08) (0.00) (0.00) (0.00) 0.549 
6 0 0 2 
H 
(n=2130)  (0.79) (0.00) (0.00) (0.45) 0.021 
17 12 12 14 
 
 
 
Gentamicin 
S 
(n=3429) (1.42) (1.62) (1.52) (1.98) 0.831 
12 8 2 5 
H 
(n=2130)  (1.58) (1.70) (0.43) (1.13) 0.197 
120 78 116 87 
 
 
 
Kanamycin 
S 
(n=3429) (10.06) (10.53) (14.72) (12.31) 0.012 
63 19 24 10 
H 
(n=2130)  (8.31) (4.04) (5.22) (2.26) (<0.001) 
1 1 0 2 
 
 
 
Nalidixic Acid 
S 
(n=3429) (0.08) (0.13) (0.00) (0.28) 0.365 
80 25 43 44 
H 
(n=2130)  (10.55) (5.32) (9.35) (9.95) 0.009 
319 184 232 182 
 
 
 
Streptomycin 
S 
(n=3429) (26.74) (24.83) (29.44) (25.74) 0.2 
122 37 43 109 
H 
(n=2130)   (16.09) (7.87) (9.35) (24.66) (<0.001) 
215 181 285 227 
 
 
 
Sulfisoxazole 
S 
(n=3429) (18.02) (24.43) (36.17) (32.11) (<0.001) 
156 68 105 87 
H 
(n=2130)  (20.58) (14.47) (22.83) (19.68) 0.008 
985 629 690 617 
 
 
 
Tetracycline 
S 
(n=3429) (82.56) (84.89) (87.56) (87.27) 0.006 
63 16 34 40 
H 
(n=2130)  (8.31) (3.40) (7.39) (9.05) 0.001 
8 5 12 14 
 
 
Trimethoprim / 
Sulfamethoxazole 
S 
(n=3429) (0.67) (0.67) (1.52) (1.98) 0.03 
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Table 9 (Continued) 
 
a 
p-values are based on a likelihood ratio chi-square test of the differences in risk 
between seasons.  These p-values are not adjusted for the dependence of responses 
within unit locations.
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Table 10   
Multi-drug resistance phenotypes of commensal E. coli isolates from human wastewater 
and swine fecal samples.  Frequency and percentage of multi-drug resistant E. coli 
isolates are presented and contrasted by host species (upper multi-resistance categories 
collapsed into 6+). 
 
Sampled by host-species
a
 (n=5559 overall sample isolates) 
Frequency of multi-drug resistant E. coli (%) 
Multi-drug 
Resistance Human Swine 
1,328 425 0 
 (62.35) (12.39) 
423 1,433 1 
 (19.86) (41.79) 
135 619 2 
 (6.34) (18.05) 
84 493 3 
 (3.94) (14.38) 
76 282 4 
 (3.57) (8.22) 
46 94 5 
 (2.16) (2.74) 
38 83 
6+ 
c 
 (1.78) (2.42) 
 
a 
Difference in the multi-drug resistant E. coli isolates between human and swine was 
significant (χ
2 
= 1600, p < 0.001) using the likelihood-ratio chi-square test
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Table 12   
 
Multi-drug resistance phenotypes of commensal E. coli isolates from human wastewater 
and swine fecal Samples.  Frequency and percentage of multi-drug resistant E. coli 
isolates are presented and contrasted by host species and season-collapsed.  Isolate 
comparisons are across all unit locations, human vocation cohorts and swine production 
groups. 
 
Sampled by season-collaped
a
  
(n=5559 overall sample isolates) 
Frequency of multi-drug resistant E. coli (%) 
Multi-drug 
Resistance 
Host 
Species 
(S=Swine, 
H=Human)
b
 
February 
  
May  
  
August 
  
November 
   
433 334 304 247 
H=1328 (58.44) (71.06) (66.09) (55.88) 
188 88 76 73 0 
S=425 (15.76) (11.88) (9.64) (10.33) 
151 80 76 116 
H=423 (19.92) (17.02) (16.52) (26.24) 
526 317 284 306 1 
S=1433 (44.09) (42.78) (36.04) (43.28) 
62 21 29 23 
H=135 (8.18) (4.47) (6.30) (5.20) 
192 148 164 115 2 
S=619 (16.06) (19.97) (20.81) (16.27) 
32 13 22 17 
H=84 (4.22) (2.77) (4.78) (3.85) 
163 111 115 104 3 
S=493 (13.66) (14.98) (14.59) (14.71) 
38 10 14 14 
H=76 (5.01) (2.13) (3.04) (3.17) 
76 52 83 71 4 
S=282 (6.37) (7.02) (10.53) (10.04) 
19 5 7 15 
H=46 (2.51) (1.06) (1.52) (3.39) 
19 12 41 22 5 
S=94 (1.59) (1.64) (5.20) (3.11) 
13 7 8 10 
H=38 (1.72) (1.49) (1.74) (2.26) 
29 13 25 16 6+ 
c
 
S=83 (2.43) (1.75) (3.17) (2.26) 
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Table 12 (Continued)  
 
a 
Difference in the multi-drug resistant E. coli human isolates and seasons was 
significant (χ
2 
= 50.51, p <0.001) using m × n likelihood-ratio chi-square test.  Also, the 
difference in multi-drug resistant E. coli swine isolates and seasons was significant (χ
2
 = 
78.04, p <0.001) using m × n likelihood-ratio chi-square test.  Both p-values are not 
adjusted for the dependence of responses within unit locations. 
b
 Number of E. coli isolates for human and swine for each multi-drug resistance 
category.  
c 
Multi-drug resistance greater than 6 antimicrobial agents (6+) was collapsed into a 
single upper category.
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swine-rearing, slaughtered pigs, and human vocation cohorts, b) breeding boars showed 
higher single-resistance levels (52.67%) and resistance to 2 or more antimicrobial agents 
(23.59%) relative to other swine and human cohorts, c) isolation boars showed higher 
level of resistance to 3, 4, and 5 antimicrobial agents (21.15%), (22.66%), and (9.06%), 
respectively relative to other swine and human cohorts, and d) nursery piglets showed 
higher level of resistance to (6+) antimicrobial agents (9.78%) relative to other swine 
and human cohorts.
 
 The multi-drug resistant E. coli isolates from human samples did 
not differ significantly (χ
2
 = 24.4, p = 0.142) among human vocation cohorts across all 
levels of multi-resistance.  However, the multi-drug resistant E. coli isolates from swine 
samples differed significantly (χ
2
 = 495.2, p < 0.001) among swine production groups 
across all levels of multi-resistance. 
4.2.   Multivariable analysis of risk factors for E. coli resistance to individual 
antimicrobial agents 
4.2.1. Comparison of E. coli resistance to individual antimicrobial agents between 
host-species 
The relative odds of resistance were significantly increased (p < 0.05) among swine 
isolates as compared to human isolates for the following antimicrobial agents:  
tetracycline (OR = 19.58, 95% CI: 16.77 – 22.86), kanamycin (OR = 10.01, 95% CI: 
5.51 – 18.23), ceftiofur (OR = 6.68, 95% CI: 2.77 – 16.10), gentamicin (OR = 4.19, 95% 
CI: 1.70 – 10.31), streptomycin (OR = 3.46, 95% CI: 2.89 – 4.15), chloramphenicol (OR 
= 2.02, 95% CI: 1.36 – 3.00), sulfisoxazole (OR = 1.99, 95% CI: 1.70 – 2.33). (Table 5, 
column 3).  In contrast, the relative odds of resistance were significantly increased
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(p < 0.05) among human isolates as compared to swine isolates for the following 
antimicrobial agents: ciprofloxacin (OR = 18.94, 95% CI: 2.79 – 128.70),  
trimethoprim/sulfamethoxazole (OR = 6.67, 95% CI: 4.74 – 9.40), and nalidixic acid 
(OR = 3.45, 95% CI: 1.94 – 6.12) (see Table 5, column 3). 
4.2.2. Comparison of E. coli resistance to individual antimicrobial agents by swine 
production group 
The relative odds of resistance were significantly increased (p < 0.05) for isolation 
boars, nursery piglets, and breeding boars E. coli isolates as compared to the swine 
referent group (slaughtered pigs) for tetracycline (OR = 12.25 (95% CI: 2.41 – 62.15), 
3.50 (95% CI: 1.08 – 11.27), and 3.20 (95% CI: 0.97 – 10.55), respectively), and 
streptomycin (OR =  2.90 (95% CI: 1.42 – 5.95), 4.96 (95% CI: 2.46 – 9.99), and 2.14 
(95% CI: 1.02 – 4.50), respectively).  Furthermore,  the relative odds of resistance were 
significantly increased (p < 0.05) for isolation boars and nursery piglets E. coli isolates 
as compared to the swine referent group (slaughtered pigs) for sulfisoxazole (OR = 5.83 
(95% CI: 3.01 – 11.34) and 4.06 (95% CI: 2.10 – 7.85)), respectively.  Table 7 provides 
the proportion of resistant E. coli by swine production group for each antimicrobial 
agent.  
4.2.3. Comparison of E. coli resistance to individual antimicrobial agents by human 
vocation cohort 
The relative odds of resistance were significantly increased (p < 0.05) among swine-
worker isolates for tetracycline (OR = 1.36, 95% CI: 0.41 – 1.57) as compared to swine 
non-workers; in contrast, the relative odds among workers were significantly lower (p < 
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0.05) for sulfisoxazole (OR = 0.73, 95% CI: 0.54 – 0.99).  The relative odds of 
resistance did not differ significantly (p > 0.05) among the non-worker/non-consumer 
and slaughter-plant worker isolates as compared to swine non-workers; however, sample 
sizes were relatively small for these human categories.  Furthermore, the relative odds of 
resistance did not differ significantly (p > 0.05) for pork consumer (i.e., swine workers, 
non-swine-workers, and slaughter-plant-workers) E. coli isolates as compared to the 
non-worker/non-consumer group. 
4.2.4. Comparison of E. coli resistance to individual antimicrobial agents by season 
There was no repeatable seasonal trend observed among the seasonal isolates (i.e., 
over all seasons, and collapsed by season) for both human and swine over the 3-year 
study period.  This conclusion was based on the variability in the GEE model parameter 
estimates for the 15 antimicrobial resistance outcomes in relation to season (see tables on 
pages 107 and 116). 
4.3.   Multivariable analysis of risk factors for E. coli resistance to multiple 
antimicrobial agents 
4.3.1. Comparison of E. coli resistance to multiple antimicrobial agents by host-species 
The relative odds of multiple resistance were significantly increased (p < 0.05) 
among swine isolates (OR = 7.33, 95% CI: 6.46 – 8.31) as compared to human isolates 
across all levels of multi-resistance.  Table 10 provides the proportion of multi-resistant 
E. coli by host-species cross-tabulated by each antimicrobial agent.
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Table 15 
Phenotypic resistance of commensal E. coli isolates from human wastewater and swine 
fecal samples.  Odds ratios of resistant E. coli isolates are presented and contrasted by 
host species and season-collapsed.  Isolate comparisons are across all unit locations, 
human vocation cohorts and swine production groups. 
 
Sampled by season-collapsed (n=5559 overall 
sample isolates) 
Odds ratio
a
 of resistant E. coli  
(p-value
b
) 
 
Antimicrobial 
agent 
Host Species 
(S=Swine, 
H=Human) Spring Summer  Autumn  
S (n=3429)
c 
 - - - 
 
 
 
Amikacin 
H (n=2130)
c 
 - - - 
S (n=3429) 
 
0.94 
 (0.849) 
1.10 
(0.765) 
0.83 
(0.624) 
 
 
 
Amoxicillin 
/Clavulanic Acid 
H (n=2130) 
 
1.86 
 (0.67) 
1.1 
 (0.82) 
1.38 
(0.41) 
S (n=3429) 
 
0.96 
(0.741) 
1.48 
(0.001) 
0.98 
(0.863) 
 
 
 
Ampicillin 
H (n=2130) 
 
0.62 
 (0.004) 
0.66 
(0.012) 
0.93 
 (0.65) 
S (n=3429) 
 
1.11 
(0.758) 
1.16 
(0.670) 
0.85 
(0.664) 
 
 
 
Cefoxitin 
H (n=2130) 
 
1.72 
(0.137) 
0.98 
(0.96) 
1.04 
(0.93) 
S (n=3429) 
 
2.19 
(0.014) 
1.37 
(0.354) 
1.42 
(0.306) 
 
 
 
Ceftiofur 
H (n=2130)
c 
 - - - 
S (n=3429)
c 
 - - - 
 
 
 
Ceftriaxone 
H (n=2130)
c 
 - - - 
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Table 15 (Continued) 
Sampled by season-collapsed (n=5559 overall 
sample isolates) 
Odds ratio
a
 of resistant E. coli  
(p-value
b
) 
 
Antimicrobial 
agent 
Host Species 
(S=Swine, 
H=Human) Spring Summer  Autumn   
S (n=3429) 
 
0.71 
(0.202) 
1.16 
(0.529) 
0.82 
(0.459) 
 
 
 
Chloramphenicol 
H (n=2130) 
 
0.41 
(0.079) 
0.41 
(0.083) 
0.96 
(0.919) 
S (n=3429)
c 
 - - - 
 
 
 
Ciprofloxacin 
H (n=2130) 
 
0.35 
(0.173) 
0.36 
(0.184) 
0.39 
(0.212) 
S (n=3429) 
 
1.29 
(0.583) 
1.43 
(0.431) 
1.68 
(0.257) 
 
 
 
Gentamicin 
H (n=2130)
c 
 - - - 
S (n=3429) 
 
0.93 
(0.656) 
1.08 
(0.612) 
1.01 
(0.968) 
 
 
 
Kanamycin 
H (n=2130) 
 
1.07 
(0.88) 
0.27 
(0.087) 
0.72 
(0.525) 
S (n=3429)
c 
 - - - 
 
 
 
Nalidixic Acid 
H (n=2130) 
 
0.40 
 (0.003) 
0.66 
 (0.069) 
0.28  
(0.001) 
S (n=3429) 
 
0.89 
(0.278) 
1.10 
(0.391) 
0.92 
(0.451) 
 
 
 
Streptomycin 
H (n=2130) 
 
0.48 
 (0.002) 
0.87 
 (0.485) 
0.93 
 (0.727) 
S (n=3429) 
 
1.40 
(0.004) 
2.18 
(<0.001) 
1.95 
(<0.001) 
 
 
 
Sulfisoxazole 
H (n=2130) 
 
0.45 
 (<0.001) 
0.54 
 (0.001) 
1.71 
 (<0.001) 
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Table 15 (Continued) 
Sampled by season-collapsed (n=5559 overall 
sample isolates) 
Odds ratio
a
 of resistant E. coli  
(p-value
b
) 
 
Antimicrobial 
agent 
Host Species 
(S=Swine, 
H=Human) Spring Summer  Autumn  
S (n=3429) 
 
1.14 
(0.244) 
1.27 
(0.047) 
1.29 
(0.038) 
 
 
 
Tetracycline 
H (n=2130) 
 
0.67 
 (0.013) 
1.2 
 (0.32) 
0.95  
(0.725) 
S (n=3429) 
 
1.01 
(0.991) 
2.32 
(0.075) 
3.03 
(0.016) 
 
 
 
Trimethoprim / 
Sulfamethoxazole 
H (n=2130) 
 
0.39 
 (0.001) 
0.88 
(0.563) 
1.10  
(0.661) 
 
a 
Odds-ratios are presented comparing the odds of season resistant E. coli isolates for 
each antimicrobial agent to winter 2004 (referent season).
  
b 
p-values are adjusted for the dependence of season isolate response within each unit 
location by using the generalized estimating equation (GEE) statistic  (STATA
TM
 ver. 
9.2, College Station, TX). 
c
 Odds-ratios were not reported because the GEE model failed to converge to report the 
parameter estimates because of the absence of positive outcome (i.e., resistance) in at 
least one season (zero cell count). 
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4.3.2. Comparison of E. coli resistance to multiple antimicrobial agents by swine 
production group 
The relative odds of multiple resistance did not differ significantly (p > 0.05).  Table 
13 provides the proportion of multi-resistant E. coli by swine production group for each 
antimicrobial agent. 
4.3.3. Comparison of E. coli resistance to multiple antimicrobial agents by human 
vocation cohort 
The relative odds of multiple resistance did not differ significantly (p > 0.05).  Table 
13 provides the proportion of multi-resistant E. coli by human vocation for each 
antimicrobial agent. 
4.3.4. Comparison of E. coli resistance to multiple antimicrobial agents by season 
The relative odds of multiple resistance did not differ significantly (p > 0.05) for 
both human and swine isolates.  Tables 11 and 12 provide the proportion of multi-
resistant E. coli by season and season-collapsed, respectively of human and swine 
isolates for each antimicrobial agent. 
4.4.  Multivariate analysis of risk factors for E. coli resistance to multiple outcomes 
4.4.1. Cluster analysis approach 
The six hierarchical agglomerative methods with a squared Euclidean distance were 
compared with cluster solutions of 10, 15, and 22 in order to identify the cluster fit that 
best described the binary data.  The method with the highest R
2
 that explained the 
highest variability and met our goal and criteria for AR phenotypic clustering was 
Ward’s minimum variance at a 15 cluster solution and with R
2
 = 0.83 (Table 16).  Other 
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hierarchical methods were not able to identify homogenous clusters as well as Ward’s 
method.  For example, single, average, centroid and median linkage methods were 
unable to identify any useful cluster structure due to the fact that CCC values were all 
negative, suggesting that the data were too sparse to be grouped by those cluster 
algorithms.  For these methods, most of the isolates were in one large cluster, and the 
rest were spread out over several clusters with 1-2 isolates per group.  However, the 
complete-linkage method with a 25-cluster solution resulted in 12 well-partitioned 
clusters, while the remaining 13 clusters had only 1 to 3 isolates each.  
The iterative partitioning k-means method was performed on both types of data with 
squared Euclidian distance proximity measure.  Using the cluster solution (n = 15) that 
was suggested by Ward’s minimum variance method, k-means produced 2 large clusters, 
and 13 small clusters.  Ward’s minimum variance method established well-defined, 
homogenous, and balanced clusters for our E. coli AR phenotypic data in their binary 
(i.e., resistant or susceptible) form, accounting for 83% of the variability (Fig. 6).  The 
distribution of the E. coli isolates’ AR phenotypes over the 15 clusters is shown in table 
on page 123.  Per our objectives, there was no single resistance pattern (phenotype) 
found in one cluster that also was assigned to another cluster.  
Forty-six (46) % of the isolates (233/504) were pan-susceptible and grouped in 
cluster A.  Single and multiple resistant phenotypes ranged from 1 to 12 antibiotics.  
Phenotypes exhibiting single resistance to ampicillin and tetracycline were found in 
clusters D and E, respectively, accounting for 7% (36/504) of the isolates.  Double 
resistance patterns existed in 28% (139/504) of the isolates and appeared in clusters 
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Table 16  
Cluster generation history for 504 E. coli isolates using Ward’s minimum variance. 
 
a 
squared multiple correlation, 
b
 cubic clustering criterion, 
c 
pseudo-F, and 
d
 pseudo-T
2
 
statistics. 
 
e
 values of pseudo-T
2
 were not reported because Je(1) (the sum of square error before   
splitting the data) was zero.
Cluster solution R
2 a 
CCC 
b 
Pseudo-F 
c 
PST2 
d 
25 0.916 76.5 217 2.8 
24 0.910 74.0 212 11.1 
23 0.904 65.0 206 6.5 
22 0.896 62.2 199 5.5 
21 0.889 59.6 193 3.0 
20 0.881 56.9 188 7.2 
19 0.872 54.5 184 5.6 
18 0.863 52.3 181 5.3 
17 0.855 50.3 179 11.6 
16 0.845 48.2 177 14.8 
15 0.834 45.9 175 3.6 
14 0.821 43.3 172 3.5 
13 0.807 41.0 172 52.4 
12 0.792 38.5 170  .
e
 
11 0.775 36.1 170  .
 e
 
10 0.755 33.1 169 6.7 
9 0.731 29.9 168 25.1 
8 0.706 27.1 170 30.5 
7 0.673 23.6 171 22.6 
6 0.637 18.2 175 25.4 
5 0.581 13.2 173 758 
4 0.511 6.74 174 94.5 
3 0.399 - 0.71 166 43.8 
2 0.238 - 4.3 157 255 
1 0.000 0.00 . 157 
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B, G and H with resistance to cephalothin combined with ceftiofur, ampicillin, or 
tetracycline, and in cluster C: nalidixic acid with tetracycline.  At least one of the 4 
antibiotics: ampicillin, cephalothin, nalidixic acid, or tetracycline was found in one or 
more of the multiple resistance clusters (B – O). 
We were unable to obtain meaningful cluster distributions that best described ordinal 
data (i.e., MIC), with or without standardization or transformation using the six 
hierarchical agglomerative and k-means approaches.  Similar resistance patterns 
(phenotypes) that were found in one cluster were also found in one or more other 
clusters, which violated our objectives.  Note that these results arose from analyses 
performed on the NARMS 2001 panels and preceded the samples described from the 
longitudinal analyses. 
4.4.2. Multivariate model of correlated dependence 
Seven antimicrobial agents were excluded from the multivariate analysis model 
because the GEE model failed to converge; that is, it failed to report the parameter 
estimates with all 15 antimicrobial agents included.  Therefore, 8 antimicrobial agents 
were included in the final analysis (Table 18).  The multivariate odds-ratios, adjusted for 
multiple binary outcomes (i.e., multivariate phenotypes), were increased relative to 
unadjusted odds-ratios among swine isolates when compared to human isolates.  This 
was especially true for tetracycline (with the highest change (increase) in odds-ratios 
compare to other antimicrobial agents) (OR = 21.8 vs. 19.6). The adjusted versus 
unadjusted odds-ratios for the other antimicrobial agents are shown in Table 18. 
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The adjusted odds-ratios of multiple binary outcomes (i.e., multivariate phenotypes) 
were increased significantly (p < 0.05) relative to unadjusted odds-ratios among swine-
worker isolates as compared to swine non-worker isolates only for tetracycline (OR = 
1.4 vs. 1.3).  The changes in adjusted odds-ratios relative to the unadjusted odds-ratios 
(increased or decreased) were variable among swine-workers and swine production 
group isolates when compared to swine non-workers (Table 18, columns 4 – 10). 
4.5. Genotypic analysis 
Repeatable standard curves, within the acceptable range of slope (-3.1 – -3.6), or 
efficiency (90 – 110%) (Chico et al., 2006), were established for both the target gene 
(blaCMY-2) and the reference gene (rpoB).  Illustration of the blaCMY-2 and rpoB gene 
standard curves is shown in Figures 7 and 8.   
The genotypic analysis of unknown community DNA samples remains incomplete 
(as of August 6, 2007) and is contingent upon resolving the problem of quantifying the 
rpoB gene, which is a single copy conserved genomic gene (Mollet et al., 1997; Dahllof 
et al., 2000).  The gene quantities (copy numbers/µl) appeared to be highly variable 
(sometimes very low relative to the blaCMY-2 copy numbers) among the community DNA 
samples extracted from both human wastewater and swine fecal matter.  This 
observation was based on the ratio of the rpoB: blaCMY-2 which ranged from 27,611:1 to 
14:1 in swine community DNA samples and 1637:1 to 18:1 in human community DNA 
samples.  Therefore, we assumed that rpoB copy numbers cannot possibly reflect what is 
expected to correspond to the number of bacterial cells in a community DNA sample.  
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The concentration of tested community DNA samples ranged from 5.0 to 35.5 ng/µl and 
from 6.0 to 40.0 ng/µl in human and swine samples, respectively.   
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CHAPTER V 
DISCUSSIO 
Our pilot cross-sectional study in 2003 – 2004 initially suggested that human 
occupational exposure to swine farms and slaughtered pigs was not associated with an 
increased risk of E. coli tetracycline resistance phenotype prevalence (Scott et al., 2005).  
However, cross-sectional studies lack a temporal component measuring the changes in 
the bacterial isolates resistance level over a long period of time.  This present study is the 
first reported to longitudinally assess the risk of elevated prevalence of AR bacteria, at 
the group-level, possibly arising from animals to humans as a result of direct 
occupational exposure to animals (i.e., swine); especially when taking into account the 
challenges that other studies were faced with (discussed in Chapter II).  To summarize 
the advantages of our system in brief, the human and swine populations had a very 
limited movement to and from the system, and occupational and food exposures were 
known.  The human populations consisted of 1) swine-workers: exposed to swine rearing 
operations or slaughtered pigs, 2) non-workers that were not exposed to swine (there was 
no mixing between worker and non-worker populations), and 3) a non-worker and non-
consumer group representing a negative control population that was sampled at several 
of the units.  All the pigs from the swine operations were slaughtered and pork products 
were fed back to human (consumers) within the system.  Pork trim were imported from 
outside the system and each lot was sampled to assess AR bacteria introduced to the 
system.  
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The target population is similar semi-closed human and swine populations systems 
in the US.  We believe that the internal validity (to obtain unbiased estimates based on 
the study data and make unbiased inferences about the associations of interest in the 
target population) of our study is strong because of the uniqueness of the study design 
and populations as well as the nature of the study system.  Also, the present study allows 
us to make inferences from the study population applicable to the target population.  
However, every study is prone to some types of bias.  In particular, we could be 
underestimating the ‘true’ prevalence and distribution of AR bacteria in human and 
swine populations because of the biases associated with the phenotypic analysis of 
wastewater and fecal matter samples.  These biases are related to: 1) the need for 
isolating the target organism, 2) missing unculturable bacterial cells that may carry 
resistance traits, 3) measuring the gene expression in vitro, 4) testing a colony out of a 
sample that contains millions of E. coli isolates, and 5) the added enrichment of the 
human wastewater sample that may favor sensitive strains over resistant strains.   
The enrichment of the human wastewater samples and not the swine fecal samples 
could potentially cause a differential misclassification bias.  This bias can occur when: 
1) E. coli bacteria shed their resistant plasmids in the enrichment broth that affecst the 
level of resistant bacteria growth on CHROM agar for human samples, 2) higher 
numbers of sensitive bacteria growth in the broth compared to resistant ones; whereas, E. 
coli bacteria were directly streaked on CHROM agar from fecal samples.  This could 
potentially bias the measure of association (OR) of human versus swine regarding 
resistance levels away from the null. 
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On the other hand, the external validity (ability to draw inferences to populations 
beyond the target population based on the study data) is questionable.  This is because 
our study agri-food system model was semi-closed in nature where: 1) human movement 
was limited, and 2) the antimicrobial use in the human and swine populations was 
different from that of the general US population (personal communication with the 
human medical officer and the swine specialist veterinarian).  Nonetheless, it is 
important not to sacrifice internal validity to gain strong external validity because it is 
worthless to extrapolate biased estimates (i.e., results) to the target population (Dohoo et 
al., 2003).   
Our study design does not follow the classic characteristics of cohort studies; rather, 
it is more appropriately termed a longitudinal study, with repeated cross-sectional 
measurements of both exposure and outcome.  In cohort studies, study subjects generally 
do not have the outcome of interest at the start of the follow-up period; therefore, 
incidence of the outcome in the cohorts defined by the exposure is compared during the 
follow-up period (Dohoo et al., 2003).  Therefore, in our study, the freedom of the study 
subjects of the outcome (i.e., the prevalence of AR bacteria) cannot be determined.  
Also, prevalence was the measure of the outcome frequency and not incidence. 
The sample collection and analysis was conducted at the group-level in this study.  
Hence, the interpretation of results and inferences were therefore also at the group-level, 
and not at the individual-level.  Studies that draw inferences at the individual-level based 
on data collected at the group-level fall into what is called ecological fallacy (Dohoo et 
al., 2003), which was not the case in our study.  The collection of group-level data was 
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preferred in our study because of: 1) the constraints on measuring resistance at the 
individual level due to: a) the ethical and security reasons related to sampling individual 
humans, and b) swine aggregate fecal samples are more representative of the large 
number of pens/pigs at different production stages than individual samples,  2) 
antimicrobial resistance is a population-based problem (both for bacteria and hosts), and 
not an individual one, and 3) the variability within groups (humans and swine) based on 
the exposure to swine is expected to be small relative to the variability among different 
groups.  That is because of the management practices within swine groups are the same 
(personal communication with the swine specialist veterinarian), and also the living 
environment and food sources (standards) are virtually the same within the exposure 
groups (e.g., workers and non-workers) within units (personal communication with the 
wastewater facilities manager). 
Assessing the risks of AR bacterial carriage due to human exposure (i.e., 
occupational) to animals and animal food products (i.e., contaminated food with AR 
bacteria) were evaluated in several cross-sectional studies (Aubry-Damon et al., 2004;  
Bates, et al., 1994; Nijsten et al., 1994; Nijsten et al., 1996b; Stobberingh et al., 1999; 
Van den Bogaard et al., 2001; Van den Bogaard et al., 2002).  These studies suggested 
that the risk of presence of AR bacteria in pig farmers or slaughter-plant workers 
increased: 1) as a result of direct exposure to reared pigs or slaughtered pigs compared to 
suburban residents (Nijsten et al., 1994), 2) as a result of farmers’ exposure to their pigs 
(Nijsten et al., 1996b), 3) in pig farmers (i.e., farmer exposure to pigs) compared to 
insurance company workers (Aubry-Damon et al., 2004), 4) as a result of exposure to 
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poultry through farming or working at poultry slaughter-plant compared to suburban 
residents (Stobberingh et al., 1999), and 5) in poultry farmers (as a result of farmers’ 
exposure to poultry) compared to poultry slaughter-plant workers (Van den Bogaard et 
al., 2001; Van den Bogaard et al., 2002).  However, these studies all faced the common 
challenges that accompany assessing the risk of transmission AR bacteria in a general 
population.  The majority of these challenges were a result of the limited or lack of 
control over the study population dynamics (movement of humans and animals), follow-
up of human cohorts or individual study subjects over time, and human travel and 
multiple sources of food products of animal origin that can potentially carry different 
resistant organisms and may introduce them to susceptible populations.  
  In our study, the swine E. coli isolates expressed greater levels of resistance to 7 
individual antimicrobial agents, as compared to human isolates, with the highest level of 
resistance to tetracycline, followed by kanamycin, ceftiofur, gentamicin, streptomycin, 
and lowest for chloramphenicol as well as sulfisoxazole.  The higher levels of resistance 
to these antimicrobial agents in swine fecal E. coli isolates compared to human 
wastewater isolates is likely associated with either past or current antimicrobial use at 
these and other swine farms (e.g., as ceftiofur sodium (injectable) and florfenicol 
(injectable)), and at a larger scale than in human medicine such for chlortetracycline (in 
feed) and neomycin (in water for nursery piglets).  On the other hand, human isolates 
were at greater probability of expressing resistance to 3 individual agents, when 
compared to swine isolates, with the highest relative odds for ciprofloxacin, followed by 
trimethoprim/sulfamethoxazole, and lowest for nalidixic acid.  Once again, this might be 
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explained by the use of these antimicrobial agents mainly in human medicine, and rarely, 
if ever, in the swine industry (especially in our study population).  Nijsten et al. (1996b) 
reported similar findings to ours, where significantly (p < 0.05) higher levels of 
resistance among swine E. coli isolates were found for oxytetracycline, streptomycin, 
sulphamethoxazole and chloramphenicol, when compared to human isolates arising from 
pig farmers.  However, none of the human isolates in their paper were at significantly (p 
< 0.05) higher levels of resistance when compared to swine, except for nalidixic acid, 
which exhibited very low, but slightly higher levels of resistance in humans (2%) than in 
swine (0%) (though not significantly (p > 0.05)).  The authors explained this as being 
due to the larger amount of total antimicrobial given to pigs at 125 mg/kg a year versus 
75 mg/kg consumed by humans.  Furthermore, the very low number of isolates resistant 
to nalidixic acid and ciprofloxacin in one or both of the host-species does not permit any 
inferences to be made.  Resistance to trimethoprim/sulfamethoxazole was not measured 
in their study and cannot be compared to our study.  Campbell et al. (2005) found that E. 
coli isolates from swine fecal matter had a higher prevalence of class 1 integrons than 
those from human wastewater; however, human isolates were more likely to harbor an 
AR gene cassette in their integrons than swine isolates.  That study was conducted in the 
same agri-food system as our study, but was limited in scope and scale. 
Swine fecal E. coli isolates exhibiting multi-drug resistance were present at higher 
levels when compared to human isolates.  Sixty-two percent of the human E. coli 
isolates were pan-susceptible, 20% were single-resistant, and 18% were resistant to 2 or 
more antimicrobial agents.  In contrast, only 13% of the swine E. coli isolates were pan-
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susceptible, 42% were single-resistant, and 45% were resistant to 2 or more 
antimicrobial agents.  The higher levels of multi-drug resistance in the swine population, 
when compared to the human population,  might be attributed to several factors: 1) 
prophylactic/subtherapeutic use of several antimicrobial agents in-feed at the swine 
farms, and 2) intensive farm management practices on swine farms that may facilitate 
the transmission, propagation, and maintenance of the AR bacterial populations.  In the 
Nijsten et al. (1996b) study, 74% of E. coli isolates from pigs showed resistance to 2 or 
more antimicrobial agents, whereas 43% of isolates from pig farmers were resistant to 2 
or more agents.  In addition, those authors reported that 15% of pig isolates were 
pansusceptible versus only 34% of those from pig farmers.  In another study, the highest 
multi-drug resistance was detected among E. coli isolates from swine, when compared to 
humans, and other domestic and wildlife isolates (Sayah et al., 2005).                                                                                                                                                                                                                                                      
The relative odds of resistance were significantly increased (p < 0.05) among swine-
worker isolates for tetracycline (OR = 1.36) when compared to non-workers, with the 
highest prevalence (25.9%) in slaughter-plant workers, followed by swine-workers 
(23.1%), non-workers (17.6%), non-workers and non-consumers (14.3%), and influent 
mixture (22.8%).  Ibekwe and Grieve (2003) reported a larger difference in the E. coli 
resistance prevalence for tetracycline between workers (pig farmers) (79%) compared to 
suburban (non-worker) residents (36%).  Van den Bogaard et al., (2001) detected higher 
oxytetracycline resistance prevalence in E. coli isolates from turkey farmers (79%) and 
broiler farmers (61%) when compared to turkey slaughter-plant workers (55%) and 
broiler slaughter-plant workers (43%).  Conversely, in our study, we detected slightly 
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higher tetracycline resistance prevalence in slaughter-plant workers when compared to 
swine-workers.  Nevertheless, the OR measure of association was significantly higher 
for tetracycline resistance in swine workers (OR = 1.36, 95% CI: 0.41 – 1.57) compared 
to swine non-workers (referent), but was not significantly different in slaughter-plant 
workers (OR = 1.17, 95% CI: 0.54 – 2.54) compared to swine non-workers.  This is 
likely because of the low number of isolates from the slaughter-plant workers (providing 
insufficient statistical power).  Therefore, to detect a statistically significant difference 
when it truly exists between the slaughter-plant worker isolates and those from non-
workers, a larger number of isolates from the former cohort would be needed (i.e., 
greater statistical power).  Thus, at this time no concrete conclusions can be made 
regarding the occupational exposure to slaughtered pigs in relation to the E. coli 
resistance prevalence in our study system. 
The relative odds of resistance did not differ significantly for E. coli AR isolates from 
pork consumers as compared to non-consumers.  Once again, the number of isolates 
from the non-consumer cohort is probably too low to detect a statistically significant 
difference when it exists (low statistical power).  Higher numbers of isolates are also 
needed from this cohort to definitively determine a difference.  Therefore, no concrete 
conclusions can be made regarding the consumer status (i.e., consumption of pork) in 
relation to the E. coli resistance prevalence.  In general, when speaking of dose (logs of 
bacteria), the risk of exposure to foodborne E. coli (e.g., pork contaminated with 
resistant bacteria) is much lower than the risk of occupational exposure to animals that 
shed AR bacteria (e.g., pigs in our study system).  This is because: 1) the slaughter-plant 
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processing techniques are designed to reduce or eliminate contamination of pork with 
AR bacteria, specifically resistant E. coli and other enteric pathogens, 2) the slaughtered 
pigs are skinned, washed rigorously after evisceration, inspected by a 3
rd
 party, meat 
parts contaminated with feces are disposed of, and pork is chilled immediately after 
processing (personal communication with the swine specialist veterinarian), 3) the 
imported pork trim had a very low E. coli prevalence (7.5%), and 4) food preparation 
(e.g., cooking) in kitchens within the units most often reduces or eliminates AR bacteria 
found on uncooked meat. 
In general, the isolation (i.e., purchased) boars showed higher levels of resistance 
compared to swine-rearing and slaughtered pigs for the following antimicrobial agents: 
ampicillin, chloramphenicol, kanamycin, sulfisoxazole, and tetracycline.  In contrast, 
nursery piglets showed higher levels of resistance than isolation boars, other swine-
rearing and slaughtered pigs for the following antimicrobial agents: cefoxitin, ceftiofur, 
gentamicin, and streptomycin.  The isolation (purchased) boars’ higher resistance levels 
relative to the swine-rearing facilities and slaughter-plant pigs may be attributed to 
unknown, but likely higher historical antimicrobial use within the outside multiplier 
units.  Furthermore, in our study population, nursery piglets received larger amounts of 
injectable antimicrobial agents compared to the other swine production groups (data not 
shown).  Dunlop et al. (1998a) reported that the individual resistance prevalences among 
E. coli isolated from finisher pigs were tetracycline (71%), sulfisoxazole (38%), 
ampicillin (29%), and gentamicin (0.6%), all of which were similar in trend to the 
resistance levels among grower-to-finisher pig isolates in our study: tetracycline 
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(83.1%), sulfisoxazole (20.6%), ampicillin (11.2%), and gentamicin (0.8%).  Mathew et 
al. (1998) found a higher prevalence of E. coli tetracycline resistance in grower pigs 
(98.8%) compared to nursery piglets (94.4%) and farrowing piglets (92%) in Tennessee 
commercial swine farms.  However, they pooled their samples by groups of four, which 
biased the resistance prevalence upwards.  Furthermore, gentamicin resistance in nursery 
piglets was higher (92.0%) when compared to grower pigs (86.0%) and farrowing 
piglets (73.9%).  However, in our study, tetracycline resistance was higher in nursery 
piglets (91%), than grower-finisher (83.1%) and farrowing sows and piglets (82.4%).  
Moreover, a similar trend among swine production groups was observed with 
gentamicin resistance prevalences in our study (was higher in nursery piglets (8.7%), 
than grower-finisher (0.8%) and farrowing sows and piglets (1.2%)) but at much lower 
resistance prevalence compared to the Mathew et al. (1998) study.  Those authors 
reported that the study commercial swine farms used oxytetracycline in-feed and 
injectable as well as gentamicin in-feed, whereas little or no gentamicin has been used in 
water and injectable in piglets, and none in feed, within the swine operation in the 
present study (personal communication with the swine specialist veterinarian).  In 
contrast to our study, Docic and Bilkei (2003) have reported that oxytetracycline was 
higher in breeding sow E. coli isolates than from fattening (i.e., grower-finisher) pigs, 
suckling (i.e., farrowing) piglets, and weaning (i.e., nursery) piglets in herds that used 
antibiotics for treatment and growth promotion.  Furthermore, those authors showed 
higher resistance levels in suckling piglets and weaning piglets to ampicillin, gentamicin 
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and sulfamethacin as compared to breeding sows and fattening pigs, which agrees with 
our study results (see Table 7).   
In our study, imported pork trim samples had very low levels of AR E. coli isolates 
(7.5%) suggesting that a very small proportion of resistant bacteria was introduced from 
outside to the system through imported pork.  To the best of our knowledge, there is no 
comparable literature data on AR bacteria level in pork trim or pork fat. 
There was a high variability observed among seasonal (winter, spring, summer, and 
autumn) samples over the 3-year period for both human and swine; both for individual 
antimicrobial agent resistance, and multi-drug resistance phenotypes.  Parveen et al. 
(2006) reported strong seasonal differences in AR prevalences for individual 
antimicrobial agents in E. coli isolates obtained from livestock (swine, dairy, poultry and 
beef) composite samples over a 1-year period.  The seasonal variability was observed 
even within livestock operations that have very similar resistance phenotypes (Parveen et 
al., 2006).  The source of the seasonal variability was not determined in their study.  We 
have ongoing analyses to determine the likely source of the seasonal variability; whether 
it be attributed to seasonal differences in historical and concurrent antimicrobial use in 
swine and human populations; or else other risk factors related to management and 
selective bacterial survival at different times of year. 
We assessed the mean number of E. coli colonies exhibiting distinctly different 
resistance phenotypes in samples collected during a single month (February 2005) for 
both host species.  The mean numbers were 2.25 and 1.98 for human wastewater and 
swine fecal samples, respectively, and the median was 2 for both.  This was similar to 
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the findings in the Berge et al. (2003) study.  Those authors reported a mean of 1.8 
phenotypes per 5 E. coli colonies from dairy calf fecal samples with a total of 5366 
isolates evaluated.  With a mean of less than 2.3, the additional resources of performing 
5 isolates per sample, and the greater interest in assessing resistance level longitudinally 
over the 3-year period, we elected instead to assess 1 isolate per sample to test for 
antimicrobial susceptibility.   
Adjusting for the dependence in the multiple binary outcomes (i.e., multivariate 
phenotypes) using the SAS macro had a variable effect on the odds-ratio values (i.e., 3 – 
53% increase or decrease) and their confidence intervals, when compared to unadjusted 
odds-ratios and confidence intervals.  In general, there was not a dramatic change in the 
odds-ratios direction (e.g., < 1 to >1 or vice versa) when adjusted for multiple binary 
outcomes.  However, the confidence interval for swine-workers did not include 1 (null 
value) when adjusted for multiple binary outcomes, indicating that the odds-ratio for 
tetracycline resistance became statistically significant when compared to non-workers.  
The changes in adjusted odds-ratios relative to the unadjusted odds-ratios were variable 
among swine-workers and swine production group isolates when compared to non-
workers (see Table 18, columns 4 – 10).   Furthermore, the adjusted odds-ratios of 
multiple binary outcomes were increased relative to unadjusted odds-ratios among swine 
isolates when compared to human isolates for tetracycline (highest change in odds-ratios 
compare to other antimicrobial agents).  Seven antimicrobial agents were excluded from 
the multivariate model because the positive outcome (i.e., resistance) was exceedingly 
rare for both human and swine isolates, and as such did not fit the error distribution 
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appropriately for asymptotic estimates.  Exact methods (e.g., Fisher's) might have 
worked better, but the SAS macro did not permit such an analysis, and software are 
lacking at this time to deal with multivariate dependent outcomes that are binary.  
Indeed, there is little or no published work that adjusts for the dependence among 
multiple binary AR outcome data.  Adjusting for the dependency among the multiple 
binary outcomes (i.e., phenotypes) is needed because of the existing correlation among 
resistant phenotypes.  For instance, an isolate that is resistant to one antimicrobial agent 
(e.g., ceftriaxone) is more likely to be resistance to another agent (e.g., ceftiofur) (Dunne 
et al., 2000).  We used an exchangeable correlation structure in the SAS macro to adjust 
for clustering (i.e., dependency) among phenotypes and within unit location.  The 
exchangeable correlation structure is used mainly when the same correlation is expected 
to exist among all pairs of observations (i.e., phenotypes) within the specified cluster 
(i.e., unit).   
Cluster analysis techniques are descriptive, non-analytical, statistical methods.  The 
goal of using this analytic approach was to describe the homogeneous groups present 
among multiple AR phenotypes based on proximity measures and cluster algorithms that 
minimized within-cluster variability and maximized between-cluster variability.  It is 
important to examine the recovered clusters to determine whether they have an isolate 
phenotype that is present in one cluster and ensure that it is not also present in another 
cluster.  There is no “best” cluster technique that works for all types of data (Milligan, 
1981).   Therefore, several cluster techniques (i.e., algorithms) should be applied to 
recover the best cluster structure in a dataset.  Furthermore, different statistical packages 
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may produce different cluster solutions, probably due to the difference in their cluster 
algorithms.  Thus, we recommend using different statistical packages to carry out the 
analysis.  In this analysis, as well in the analysis described Berge et al. (2003), Ward’s 
minimum variance with squared Euclidian distance produced well separated 
homogenous clusters.  Those authors used disk diffusion method to assess the isolates’ 
antimicrobial susceptibility; as a result, this approach produced continuous 
measurements.  In his Monte Carlo simulations, evaluating several cluster analysis 
approaches, Milligan (1981) supported our finding that Ward’s minimum is the best 
method to produce well separated clusters on binary and continuous data.  
We applied the cluster algorithms on both ordinal (MIC) and binary AR data in order 
to assess the ability of those algorithms to recover structured clusters as well as to 
determine if they were as useful as when applied to continuous data (Berge et al., 2003).  
Cluster algorithms were unable to group MIC values (i.e., ordinal data) into well-
separated clusters.  We believe that the nature of these ordinal data (i.e., with 2-fold 
differences in antimicrobial agent concentrations per dilution, and variable numbers of 
dilutions per antimicrobial on the NARMS panels) caused instability in the cluster 
algorithms which resulted in non-homogenous clusters that did not represent the data 
properly.  Also, not all antimicrobial agents had multiple cutpoints and our sample size 
was small. 
The 504 E. coli isolates in the human wastewater data set contained 57 uniquely 
different resistance patterns.  These patterns ranged from pansusceptible through single 
and multiple resistance of up to 12 antimicrobial agents.  Theoretically, in an E. coli 
  
143 
isolate data set of infinite size, when assessing phenotypic resistance to 15 antimicrobial 
agents (and assuming a completely random process), there could be a maximum of 2
15
 =  
32,768 possible unique phenotypes.  Obviously, biological features (e.g., actual 
existence of resistance mechanisms, shared mechanisms for multiple antimicrobial 
agents of the same class, samples size) restrict the possibilities to a much lower number.  
Other factors may also reduce the number of possible phenotypes.  For example, 
resistance genes often are suggested to be genetically linked in bacterial isolates (Mazel 
and Davies, 1999).  Bacterial exposure to an antimicrobial agent may cause the organism 
to express resistance to multiple antibiotics that could be genetically related.  Also, 
resistance may persist due to the genetic linkage of several AR genes, providing for their 
continued existence even as antimicrobial selection pressures change (Salyers et al., 
1997).  The clusters we obtained represent “groupings” among the resistance phenotypes 
that might point to the possibility of AR genetic linkage in the bacterial isolates (i.e., 
genotype).  Poole et al. (2005) found that 46% of the VRE bacteria isolated from human 
wastewater samples at 4 units with swine operations in our study system, were clonal 
based on the PFGE analysis.  This points to the possibility of clustering among AR 
bacteria isolated from different locations.  
Several issues related to cluster analysis of multiple AR resistant phenotypes should 
be discussed in conjunction with this type of analysis.  First, one should consider 
whether the resulting clusters reflected the underlying biological distribution of the 
phenotypes (i.e., biologically meaningful clusters).  For instance, some of the resistant 
phenotypes that are known to be genetically linked (e.g., ceftiofur and ceftriaxone) were 
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grouped in one cluster reflecting the underlying genotypic linkage.  However, other 
phenotypes (e.g., tetracycline and nalidixic acid) found in one cluster may not actually 
be genetically linked.  Second, the repeatability of the cluster analysis results, when 
cluster techniques are applied to different data sets, should be assessed.  That is, to say, 
whether the resulting clusters from those data sets will be similar or different.  
Repeatability may be assessed using bootstrapping technique (re-sampling with 
replacement from the original data set); that is, using a random sampling of a subset 
from the original data set, then performing cluster analysis on those sampled data sets, or 
using an entirely different data set, and then comparing the results of the analysis.  Third, 
cluster analysis techniques initially assume that resistance phenotypes are considered to 
be independent.  However, due to the correlation among resistant phenotypes, the 
assumption of initial independence is not likely to hold.  Fourth, sorting the resistance 
clusters in ascending order on an ordinal scale low-to-high resistance clusters, may be 
misleading.  This is an issue where, for example, more than one single-resistance cluster 
or more than one cluster with resistance to 2 antimicrobial agents are obtained by the 
analysis.  Cluster analysis was performed on AR phenotypes on a continuous scale by 
Berge et al. (2003).  However, several of these issues addressed above were not 
discussed by the authors; such as the repeatability of the cluster methods across datasets 
and the assumption of independence among phenotypes. 
Broth microdilution and disk diffusion procedures are two common in vitro methods 
used to test bacterial isolate susceptibility to one or more antimicrobial agents at 
different concentrations.  We chose the microdilution approach over the disk diffusion 
  
145 
method to test our isolates because of: 1) the reproducibility of the results due to the 
antibiotic panel manufacturing process assuring precise repeatable concentrations, 2) the 
expediency of having prepared panels available when required, 3) the combined 
generation of semi-quantitative (i.e., MIC values) and interpreted qualitative data 
(susceptible vs. resistant), 4) the availability of a computerized automated recording and 
reporting system that reduces intra- and inter-operator variability, and 5) ability to 
compare with NARMS results (Jorgensen and Ferraro, 1998).  Semi-quantitative results 
are important in order to monitor small shifts in susceptibility at the population level.  
Therefore, MIC values are more precise measures that can reflect slight changes in 
susceptibility compared to the categorical data.  This represents the first application of 
cluster techniques among non-continuous AR data.  Many antimicrobial resistance 
studies lack the use of MIC values in their analyses due to the difficulties that arise from 
the nature of these types of data.  However, at this point the question of how to group 
MIC data into meaningful clusters remains unresolved. 
The marginal (i.e., population-averaged) GEE model was used to assess the 
relationship between the individual or multi-drug resistance phenotypes and the risk 
factors at the group-level, assuming this relation is the same for all subjects within 
clusters.  Subject-specific (i.e., random effect) models assume that the relationship 
between the outcome and the predictors (i.e., risk factors) differs between subjects 
within clusters (Carriere and Bouyer, 2002; Dohoo et al., 2003).  In our study, the 
samples were collected at the group-level for the human and swine populations.  The 
GLLAMM models have the advantage of adjusting for multi-level hierarchical 
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clustering (i.e., dependency) in the data (Rabe-Hesketh et al., 2004).  This type of 
hierarchical clustering exists in our data where host-species/farms/pens are nested within 
unit.  The GEE models have major drawbacks in that it can only adjust for 1-level of 
clustering.  Also, the within-cluster variability can not be estimated using GEE (Hanley 
et al., 2003).  It has been suggested that alternating logistic regression (ALR) can adjust 
for multi-level clustering in the data such as dependency within unit, and dependency in 
farms/pens nested within unit using a population-averaged model (Carey et al., 1993).  
Alternating logistic regression is a marginal model that adjusts for multi-level clustered 
binary data by alternating between generalized estimating equations and logistic 
regression models to estimate the odds-ratios across and within clusters (Carey et al., 
1993).  However, the ALR model failed to converge when applied to our data (data not 
shown).  That was likely due to the data structure where multiple E. coli bacteria isolated 
from multiple locations within unit were measured repeatedly at each time point 
(season).   
Our qPCR methodology has focused primarily, but not strictly limited to, 
quantifying the blaCMY2 gene in total community DNA samples extracted from human 
wastewater and swine fecal matter.  This gene is known to code for resistance to 
ceftiofur (an antimicrobial agent used in animal agriculture) and possibly to other 3
rd
 
generation cephalosporins such as ceftriaxone, which is commonly used in human 
medicine (Tragesser et al., 2006).  The blaCMY2 gene is the most frequently described 
plasmid-encoded AmpC cephalosporinase (Bauernfeind et al., 1998).  Also, it is the 
most prevalent cephalosporin gene and has been found in many areas of the world 
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(Philippon et al., 2002).  This gene is mostly found to reside on bacterial plasmids, 
integrons, and transposons (Archambault et al., 2006; Winokur et al., 2001) and has been 
detected in both human and animal (e.g., swine) E. coli isolates (Alcaine et al, 2005).  It 
has been suggested that the blaCMY-2 plasmid gene disseminates rapidly among different 
bacterial species in addition to the possible transmission of those bacteria from animals 
to human (Winokur et al., 2001).   
Our chosen reference gene (rpoB) exists in a single copy per bacterial cell 
overcoming the inherent heterogeneity in copy/cell problem of 16S rDNA (Mollet et al., 
1997; Dahllof et al., 2000).  Standardization (i.e., normalization) of the target gene copy 
numbers to the reference gene copy numbers is crucial in this type of quantitative PCR 
analysis.  This is because of the variability in the amount of bacterial- and non-bacterial-
DNA present in the total community DNA samples (e.g., human cells, plants, algae).  
Thus, quantifying the bacterial cell copy numbers (i.e., background), which gives rise to 
the target gene, is necessary for standardization. 
The high variability in the rpoB gene copy numbers that was reported in our study 
may be attributed to the community DNA extraction efficiency and/or to the 
quantification methodology of the genomic-conserved sequence in total community 
DNA samples using the SYBR® Green assay.  Further research is needed to enhance the 
extraction efficiency to yield more bacterial DNA, concentrate the total community post 
extraction, perhaps use immunomagnetic beads coated with anti-E. coli to capture this 
organism, reduce PCR inhibitors in community DNA samples, and to optimize the PCR 
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parameters (e.g., primer sequence and concentration, and design) to enhance gene 
recovery. 
There have been no published studies that quantified the absolute copy numbers of a 
target gene in total community DNA and standardized that to copy numbers of an 
appropriate house-keeping (i.e., reference) gene.  Several studies have quantified either 
the number of rRNA genes in community DNA samples, based on the number of 
specific bacterial isolates (e.g., E. coli CFU or cells/g or ml) in the original raw sample, 
or the number of gene(s) in community DNA samples, with or without standardization 
(Khan et al., 2007; Ibekwe and Grieve, 2003; Smith et al., 2004; Castillo et al., 2006).  
Although Smith et al. (2004) have reported the log copy numbers for 3 tetracycline 
genes in feedlot lagoon community DNA, the authors did not standardize the target 
genes properly; rather, they used the volatile suspended solids (VSS) method, for 
standardizing the sample-to-sample variations.  Moreover, the number of rRNA genes 
(e.g., 16S rDNA) based on the number E. coli bacterial isolates is not a proper method to 
use to standardize a target gene in community DNA because of the biases associated 
with it.  For example, if this method was applied to our samples, the biases would be 
associated with 1) isolating E. coli from wastewater and fecal samples compared to 
community DNA, 2) the need for enrichment of wastewater before culturing, and 3) that 
the blaCMY2 gene exists in different bacterial species and not only in E. coli bacteria.  
Molecular methods have the advantage of: 1) assessing the AR gene copies present 
(not simply the expression) even from dead and unculturable bacterial cells, 2) they are 
rapid and reliable in assessing resistance genes, and 3) there is no need to isolate the 
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bacteria when, for instance; total community DNA is used.  Our future research will 
focus on quantifying and tracking longitudinally unique genotypes (e.g., blaCMY2) in the 
total community DNA extracted from wastewater and fecal matter samples to better 
assess the AR transmission dynamic in human and swine populations, and relation to 
associated antimicrobial use in each species.   
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CHAPTER VI 
COCLUSIOS 
This is the first longitudinal study conducted to assess the risk of transmission of AR 
bacteria due to human occupational exposure to swine or antimicrobials in feed in a 
multi-site vertically integrated agri-food system.  The study design and sample collection 
strategy surpassed the existing related AR research that addressed the risk of resistant 
bacterial transmission to humans as a result of direct contact with animals.  That is 
because: 1) our study populations had limited movement to and from the system (semi-
closed agri-food system), 2) the study subjects (humans and pigs) exposure to other 
subjects within the study area was limited, and 3) pork was produced, processed, and 
consumed within the system with some pork trim imports.  Our previous pilot cross-
sectional study suggested that occupational exposure to swine was not associated with E. 
coli tetracycline resistance phenotype prevalence.  However, in this longitudinal study 
(over the 3-year period) occupational exposure to swine-rearing appeared to be 
associated only with tetracycline resistance when compared to non-workers.  These 
findings might be attributed to the high tetracycline resistance prevalence in the swine 
production groups that the workers were exposed to, as compared to the other 
antimicrobial agents resistance prevalences.  Or, the exposure of the swine-workers to 
the agent itself (i.e., chlortetracycline in feed) through ingestion or inhaling the dust 
from the medicated feed may be to blame.  Thus, this may indicate that occupational 
exposure to swine rearing facilities could be a risk for AR bacteria carriage by humans.  
  
151 
In general, 1) the swine E. coli isolates across all units were at higher level of resistance 
than humans, 2) the swine production group resistance isolates differed significantly 
with highest levels in purchased boars, breeding boars and nursery piglets.  Adjusting for 
the dependence within multivariate phenotypes using the multivariate model of 
correlated dependence had an elevating effect on the odds-ratios and their confidence 
intervals before adjustment.  Seasonal effect was highly variable over the 3-year study 
period.  We have ongoing analyses to evaluate the relationship between AR seasonal 
variability and the historical use of antimicrobial agents in both host species.  
In the future, the use of molecular epidemiology; that is utilization of molecular 
biology principles and techniques in epidemiologic research to better understand disease 
determinants and distribution at the exposure and outcome level, is needed.  It is 
imperative to be able to track unique resistance gene(s) over time to obtain better 
quantitative data in order to enhance our understanding of those factors impacting the 
distribution of AR bacteria and ultimately to better assess AR bacteria transmission in 
the study system.   
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